Mirna-based predictive models for diagnosis and prognosis of prostate cancer

ABSTRACT

The lack of clear predictors of prostate cancer progression leads to subjective decision-making regarding courses of treatment. The identification of new biomarkers that are predictive of recurrence after radical prostatectomy would advance the field of prostate cancer treatment. Disclosed are miRNAs that can be used as molecular biomarkers to detect or predict the progression of prostate cancer and to adjust a treatment plan accordingly. Furthermore, kits are included for the detection of these miRNAs.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 62/103,288, filed Jan. 14, 2015, which is hereby incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government Support under Grant No. CA180850 and Grant No. CA188500, awarded by the National Institutes of Health. The Government has certain rights in the invention.

BACKGROUND

Prostate cancer (PCa) is one of the most common cancers worldwide and the most common cancer in men. However, treatment strategies remain highly controversial. Radical prostatectomy (RP), or complete removal of the prostate gland, is a common treatment option for men with early-stage PCa. Long-term data indicate that 30-40% of these patients experience rising prostate-specific antigen (PSA) levels after RP, indicating continued survival of prostate cells. A significant rise in PSA level after RP may be termed a “biochemical failure” (BF), “biochemical recurrence”, or “biochemical relapse”. At this point, a patient may opt for salvage radiation therapy (RT), adjuvant therapy, or both, depending on the prognosis from the clinician. For some patients, BF may occur again after the second round of therapy.

Currently, data used to develop prognoses after RP and RT include PSA levels, age, pathologic tumor (pT) and lymph node (pN) classification, and Gleason score. PSA is manufactured by cells of the prostate gland. A rising PSA level is considered a potential indicator of prostate cancer. Tumor stage (pT) indicates the size and invasiveness of the tumor (on a scale of 1-4, 1 being smallest and least invasive). The lymph node score (pN) indicates whether or not the cancer has spread to the lymph nodes near the prostate gland. This value is either a 0 if the cancer is not present in the lymph nodes, or a 1 if the cancer is found in the lymph nodes.

The Gleason score takes into account the ability of the tumor to form glands (an indication of healthier tissue). A pathologist assigns a primary grade based on the most prominent tissue seen in the tumor, and a secondary grade based on the second most prominent or the most aggressive types of tissue seen in the tumor. The range of grades is 1-5: 1, 2 and 3 are considered to be low to moderate in grade (many smaller, more uniform glands); 4 and 5 are considered to be high grade (few glands). The prognosis for a given patient generally falls somewhere between that predicted by the primary grade and a secondary grade given to the second most prominent glandular pattern. When the two grades are added the resulting number is referred to as the Gleason score. The Gleason Score is a more accurate predictor of outcome than either of the individual grades. Thus, the traditionally reported Gleason score will be the sum of two numbers between 1-5 with a total score from 2-10.

Multiple risk assessment nomograms and classification models have been derived utilizing parameters such as the pT, pN, Gleason score, or resection status. These models include the CAPRA score, Partin table, D'Amico classification, and the three Stephenson Nomograms. However, it is still difficult to distinguish between aggressive and indolent prostate cancers. The lack of clear predictors of prostate cancer progression leads to subjective decision-making regarding courses of treatment. Some prostate tumors grow so slowly that they never cause life threatening problems, making early-stage treatment controversial. Therefore, biomarkers that predict the progression of PCa are needed to guide therapy.

SUMMARY

Disclosed are methods of using miRNAs as molecular biomarkers to predict the progression of a patient's cancer and adjust their therapeutic regimen accordingly. Methods include predicting biochemical recurrence in a subject following radical prostatectomy. This may include determining a miRNA expression profile from a sample (e.g., tumor biopsy or bodily fluid) from the subject of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, or 88 of the miRNA listed in Table 2 and calculating a recurrence risk score from the miRNA expression profile. A high recurrence risk score can be an indication of biochemical recurrence within 1-5 years.

Methods also include predicting biochemical recurrence in a subject following post-prostatectomy salvage radiation therapy, including external beam radiation therapy or internal radiation therapy. This may include determining a miRNA expression profile from a sample from the subject of at least 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the miRNA listed in Table 3 and calculating a recurrence risk score from the miRNA expression profile. In some embodiments, the miRNAs include miR-4516, miR-601, or a combination thereof, alone or in combination with any of the miRNAs listed in Table 3. A high recurrence risk score can be an indication of biochemical recurrence within 1-5 years.

Methods may also include grading the tumor biopsy according to a Gleason score, and using the Gleason score as a covariate in calculating the recurrence risk score. Methods may also include determining the lymph node classification, the pathologic tumor classification, and/or the resection status, and using these properties as covariates in calculating the recurrence risk score.

If the recurrence risk score is high, methods may include treating the subject with radical prostatectomy, radiation therapy, or adjuvant treatment. The adjuvant therapy may be chemotherapy, hormone therapy, biologic therapy, radiation therapy or a combination thereof. The radiation therapy may be salvage radiation therapy, including external beam radiation therapy or internal radiation therapy. Methods may also include treating a patient with palliative care if the recurrence risk score is high. If the recurrence risk score is low, treatment methods may include continued clinical monitoring.

Also disclosed are methods of using miRNA biomarkers to detect prostate cancer in a subject. In some embodiments, the method involves determining a miRNA expression profile from a sample from the subject that includes at least miRNA-1283, miRNA-137, or a combination thereof. This method may further include comparing the miRNA expression intensities to pre-specified levels and using these levels to reach a diagnosis. The step of reaching a diagnosis may also include determining a PSA level and/or taking a prostate biopsy. If the method detects prostate cancer, the method may further include administering a treatment such as surgical treatment, radiation treatment, adjuvant treatment, or a combination thereof.

For all methods, the sample used to detect or prognose prostate cancer may be a bodily fluid or a tumor.

In some embodiments, a kit may be used to determine an miRNA expression profile of a subject, the kit comprising oligonucleotide primers or probes configured to selectively bind to 2 or more miRNA listed in Table 1, Table 2, Table 3, or a combination thereof.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 shows a Venn diagram of the numbers of commonly and differentially expressed miRNAs in prostate tumor, stroma, and epithelium.

FIG. 2 shows a Venn diagram of the numbers of miRNAs commonly expressed among all tissue types (tumor, epithelium, and stroma), and lists by name those significantly differentially expressed 1.5-fold or greater between all tissues types.

FIG. 3A shows a cluster analysis of 88 miRNAs predictive of first biochemical recurrence. The analysis may distinguish markers relating to early versus late recurrence after radical prostatectomy.

FIG. 3B shows a Kaplan-Meier plot of the cluster analysis in FIG. 3A

FIG. 4 shows an area under the receiver operating characteristic curve (AUC) of a miRNA-based predictive salvage RT model.

FIG. 5 shows a Kaplan-Meier plot for distinguishing early versus late recurrence after salvage radiation therapy.

FIG. 6 shows a flow chart of the study design used in the example.

DETAILED DESCRIPTION

The lack of clear predictors of prostate cancer progression leads to subjective decision-making regarding courses of treatment. The identification of new biomarkers that can detect prostate cancer and predict recurrence post-RP would advance the field of PCa treatment. Disclosed herein are methods of using miRNAs as molecular biomarkers to detect and predict the progression of a patient's cancer and adjust their therapeutic regimen accordingly.

Disclosed are miRNA biomarkers which may be used to detect prostate cancer in a subject and/or predict its recurrence following therapy. The term “subject” refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician.

In some embodiments, the biological sample used for determining the level of one or more miRNA biomarkers is a tumor sample containing miRNAs. The tumor sample may be freshly isolated or may have been preserved by methods known in the art, including but not limited to formalin fixation with paraffin embedding. In some embodiments, the biological sample used for determining the level of one or more miRNA biomarker is a tissue biopsy. In other embodiments, the biological sample contains circulating miRNAs, e.g., extracellular miRNAs. Circulating miRNAs include miRNAs in cells (cellular miRNA), extracellular miRNAs in microvesicles (microvesicle-associated miRNA), and extracellular miRNAs that are not associated with cells or microvesicles (extracellular, non-vesicular miRNA).

Extracellular miRNAs freely circulate in a wide range of bodily fluids. Accordingly, in some embodiments, the biological sample used for determining the level of one or more miRNA biomarkers is a bodily fluid, such as blood, fractions thereof, serum, plasma, urine, saliva, tears, sweat, semen, lymph, bronchial secretions, or CSF. In some embodiments, the sample is a sample that is obtained non-invasively. In some embodiments, the biological sample used for determining the level of one or more miRNA biomarkers may contain cells. In other embodiments, the biological sample may be free or substantially free of cells (e.g., a serum or plasma sample). The sample may likewise be free or substantially free of microvesicles. For example, a sample that is free or substantially free of microvesicles is one in which the microvesicle content of the sample is sufficiently low to avoid interfering with the ability to accurately determine the level of non-vesicular miRNAs in the sample.

The level of one or more miRNA biomarkers in a biological sample may be determined by any suitable method. Any reliable method for measuring the level or amount of miRNA in a sample may be used. Generally, miRNA can be detected and quantified from a sample (including fractions thereof), such as samples of isolated RNA by various methods known for mRNA detection, including, for example, amplification-based methods (e.g., Polymerase Chain Reaction (PCR), Real-Time Polymerase Chain Reaction (RT-PCR), Quantitative Polymerase Chain Reaction (qPCR), rolling circle amplification, etc.), hybridization-based methods (e.g., hybridization arrays (e.g., microarrays), NanoStringm analysis, Northern Blot analysis, branched DNA (bDNA) signal amplification, and in situ hybridization), and sequencing-based methods (e.g. next-generation sequencing methods, for example, using the Illumina or IonTorrent platforms). Other exemplary techniques include ribonuclease protection assay (RPA) and mass spectroscopy.

In some embodiments, RNA is converted to DNA (cDNA) prior to analysis. cDNA can be generated by reverse transcription of isolated miRNA using conventional techniques. miRNA reverse transcription kits are known and commercially available. Examples of suitable kits include, but are not limited to the mirVana TaqMan® miRNA transcription kit (Ambion, Austin, Tex.), and the TaqMan® miRNA transcription kit (Applied Biosystems, Foster City, Calif.). Universal primers, or specific primers, including miRNA-specific stem-loop primers, are known and commercially available, for example, from Applied Biosystems. In some embodiments, miRNA is amplified prior to measurement. In other embodiments, the level of miRNA is measured during the amplification process. In still other embodiments, the level of miRNA is not amplified prior to measurement. Some exemplary methods suitable for determining the level of miRNA in a sample are described in greater detail below. These methods are provided by way of illustration only, and it will be apparent to a skilled person that other suitable methods may likewise be used.

Many amplification-based methods exist for detecting the level of miRNA nucleic acid sequences, including, but not limited to, PCR, RT-PCR, qPCR, and rolling circle amplification. Other amplification-based techniques include, for example, ligase chain reaction, multiplex ligatable probe amplification, in vitro transcription (IVT), strand displacement amplification, transcription-mediated amplification, RNA (Eberwine) amplification, and other methods that are known to persons skilled in the art.

A typical PCR reaction includes multiple steps, or cycles, that selectively amplify target nucleic acid species: a denaturing step, in which a target nucleic acid is denatured; an annealing step, in which a set of PCR primers (i.e., forward and reverse primers) anneal to complementary DNA strands, and an elongation step, in which a thermostable DNA polymerase elongates the primers. By repeating these steps multiple times, a DNA fragment is amplified to produce an amplicon, corresponding to the target sequence. Typical PCR reactions include 20 or more cycles of denaturation, annealing, and elongation. In many cases, the annealing and elongation steps can be performed concurrently, in which case the cycle contains only two steps. A reverse transcription reaction (which produces a cDNA sequence having complementarity to a miRNA) may be performed prior to PCR amplification. Reverse transcription reactions include the use of, e.g., a RNA-based DNA polymerase (reverse transcriptase) and a primer. Kits for quantitative real time PCR of miRNA are known, and are commercially available. Examples of suitable kits include, but are not limited to, the TaqMan® miRNA Assay (Applied Biosystems) and the mirVana™ qRT-PCR miRNA detection kit (Ambion). The miRNA can be ligated to a single stranded oligonucleotide containing universal primer sequences, a polyadenylated sequence, or adaptor sequence prior to reverse transcriptase and amplified using a primer complementary to the universal primer sequence, poly(T) primer, or primer comprising a sequence that is complementary to the adaptor sequence.

In some instances, custom qRT-PCR assays can be developed for determination of miRNA levels. Custom qRT-PCR assays to measure miRNAs in a biological sample, e.g., a tumor or a bodily fluid, can be developed using, for example, methods that involve an extended reverse transcription primer and locked nucleic acid modified PCR. Custom miRNA assays can be tested by running the assay on a dilution series of chemically synthesized miRNA corresponding to the target sequence. This permits determination of the limit of detection and linear range of quantitation of each assay. Furthermore, when used as a standard curve, these data permit an estimate of the absolute abundance of miRNAs measured in biological samples.

Amplification curves may optionally be checked to verify that Ct values are assessed in the linear range of each amplification plot. Typically, the linear range spans several orders of magnitude. For each candidate miRNA assayed, a chemically synthesized version of the miRNA can be obtained and analyzed in a dilution series to determine the limit of sensitivity of the assay, and the linear range of quantitation. Relative expression levels may be determined, for example, according to the 2(−ΔΔ C(T)) method.

In some embodiments, two or more miRNAs are amplified in a single reaction volume. For example, multiplex q-PCR, such as qRT-PCR, enables simultaneous amplification and quantification of at least two miRNAs of interest in one reaction volume by using more than one pair of primers and/or more than one probe. The primer pairs comprise at least one amplification primer that specifically binds each miRNA, and the probes are labeled such that they are distinguishable from one another, thus allowing simultaneous quantification of multiple miRNAs.

Rolling circle amplification is a DNA-polymerase driven reaction that can replicate circularized oligonucleotide probes with either linear or geometric kinetics under isothermal conditions. In the presence of two primers, one hybridizing to the (+) strand of DNA, and the other hybridizing to the (−) strand, a complex pattern of strand displacement results in the generation of over 10⁹ copies of each DNA molecule in 90 minutes or less. Tandemly linked copies of a closed circle DNA molecule may be formed by using a single primer. The process can also be performed using a matrix-associated DNA. The template used for rolling circle amplification may be reverse transcribed. This method can be used as a highly sensitive indicator of miRNA sequence and expression level at very low miRNA concentrations.

miRNA may also be detected using hybridization-based methods, including but not limited to hybridization arrays (e.g., microarrays), NanoString™ analysis, Northern Blot analysis, branched DNA (bDNA) signal amplification, and in situ hybridization.

Microarrays can be used to measure the expression levels of large numbers of miRNAs simultaneously. Microarrays can be fabricated using a variety of technologies, including printing with fine-pointed pins onto glass slides, photolithography using pre-made masks, photolithography using dynamic micromirror devices, ink-jet printing, or electrochemistry on microelectrode arrays. Also useful are microfluidic TaqMan Low-Density Arrays, which are based on an array of microfluidic qRT-PCR reactions, as well as related microfluidic qRT-PCR based methods.

In one example of microarray detection, various oligonucleotides (e.g., 200+ 5′-amino-modified-C6 oligos) corresponding to human sense miRNA sequences are spotted on three-dimensional CodeLink slides (GE Health/Amersham Biosciences) at a final concentration of about 20 μM and processed according to manufacturer's recommendations. First strand cDNA synthesized from 20 μg TRIzol-purified total RNA is labeled with biotinylated ddUTP using the Enzo BioArray end labeling kit (Enzo Life Sciences Inc.). Hybridization, staining, and washing can be performed according to a modified Affymetrix Antisense genome array protocol.

Axon B-4000 scanner and Gene-Pix Pro 4.0 software or other suitable software can be used to scan images. Non-positive spots after background subtraction, and outliers detected by the ESD procedure, are removed. The resulting signal intensity values may be normalized to per-chip median values and then used to obtain geometric means and standard errors for each miRNA. Each miRNA signal can be transformed to log base 2, and a one-sample t test can be conducted. Independent hybridizations for each sample can be performed on chips with each miRNA spotted multiple times to increase the robustness of the data.

Microarrays can be used for the expression profiling of miRNAs in diseases. For example, RNA can be extracted from a sample and, optionally, the miRNAs are size-selected from total RNA. Oligonucleotide linkers can be attached to the 5′ and 3′ ends of the miRNAs and the resulting ligation products are used as templates for an RT-PCR reaction. The sense strand PCR primer can have a fluorophore attached to its 5′ end, thereby labeling the sense strand of the PCR product. The PCR product is denatured and then hybridized to the microarray. A PCR product, referred to as the target nucleic acid that is complementary to the corresponding miRNA capture probe sequence on the array will hybridize, via base pairing, to the spot at which the capture probes are affixed. The spot will then fluoresce when excited using a microarray laser scanner.

The fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular miRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular miRNA.

Total RNA containing the miRNA extracted from a sample can also be used directly without size-selection of the miRNAs. For example, the RNA can be 3′ end labeled using T4 RNA ligase and a fiuorophore-labeled short RNA linker. Fluorophore-labeled miRNAs complementary to the corresponding miRNA capture probe sequences on the array hybridize, via base pairing, to the spot at which the capture probes are affixed. The fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular miRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular miRNA.

Several types of microarrays can be employed including, but not limited to, spotted oligonucleotide microarrays, pre-fabricated oligonucleotide microarrays or spotted long oligonucleotide arrays.

miRNAs can also be detected without amplification using the nCounter® Analysis System (NanoString™ Technologies, Seattle, Wash.). This technology employs two nucleic acid-based probes that hybridize in solution (e.g., a reporter probe and a capture probe). After hybridization, excess probes are removed, and probe/target complexes are analyzed in accordance with the manufacturer's protocol. nCounter® miRNA assay kits are available from NanoString™ Technologies, which are capable of distinguishing between highly similar miRNAs with great specificity.

miRNAs can also be detected using branched DNA (bDNA) signal amplification (see, for example, Urdea, Nature Biotechnology (1994), 12:926-928). miRNA assays based on bDNA signal amplification are commercially available. One such assay is the QuantiGene® 2.0 miRNA Assay (Affymetrix, Santa Clara, Calif.).

Northern Blot and in situ hybridization may also be used to detect miRNAs. Suitable methods for performing Northern Blot and in situ hybridization are known in the art.

Advanced sequencing methods can likewise be used as available. For example, miRNAs can be detected using Illumina® Next Generation Sequencing (e.g., Sequencing-By-Synthesis or TruSeq methods, using, for example, the HiSeq, HiScan, GenomeAnalyzer, or MiSeq systems (Illumina, Inc., San Diego, Calif.)). miRNAs can also be detected using Ion Torrent Sequencing (Ion Torrent Systems, Inc., Gulliford, Conn.), or other suitable methods of semiconductor sequencing.

Mass spectroscopy can also be used to quantify miRNA using RNase mapping. Isolated RNAs can be enzymatically digested with RNA endonucleases (RNases) having high specificity (e.g., RNase TI, which cleaves at the 3′-side of all unmodified guanosine residues) prior to their analysis by MS or tandem MS (MS/MS) approaches. The first approach developed utilized the on-line chromatographic separation of endonuclease digests by reversed phase HPLC coupled directly to ESTMS. The presence of posttranscriptional modifications can be revealed by mass shifts from those expected based upon the RNA sequence. Ions of anomalous mass/charge values can then be isolated for tandem MS sequencing to locate the sequence placement of the posttranscriptionally modified nucleoside.

Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has also been used as an analytical approach for obtaining information about post-transcriptionally modified nucleosides. MALDI-based approaches can be differentiated from EST-based approaches by the separation step. In MALDI-MS, the mass spectrometer is used to separate the miRNA.

To analyze a limited quantity of intact miRNAs, a system of capillary LC coupled with nanoESI-MS can be employed, by using a linear ion trap-orbitrap hybrid mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific) or a tandem-quadrupole time-of-flight mass spectrometer (QSTAR® XL, Applied Biosystems) equipped with a custom-made nanospray ion source, a Nanovolume Valve (Valco Instruments), and a splitless nano HPLC system (DiNa, KYA Technologies). Analyte/TEAA is loaded onto a nano-LC trap column, desalted, and then concentrated. Intact miRNAs are eluted from the trap column and directly injected into a CI 8 capillary column, and chromatographed by RP-HPLC using a gradient of solvents of increasing polarity. The chromatographic eluent is sprayed from a sprayer tip attached to the capillary column, using an ionization voltage that allows ions to be scanned in the negative polarity mode.

Additional methods for miRNA detection and measurement include, for example, strand invasion assay (Third Wave Technologies, Inc.), surface plasmon resonance (SPR), cDNA, MTDNA (metallic DNA; Advance Technologies, Saskatoon, SK), and single-molecule methods such as the one developed by US Genomics. Multiple miRNAs can be detected in a microarray format using a novel approach that combines a surface enzyme reaction with nanoparticle-amplified SPR imaging (SPRI). The surface reaction of poly(A) polymerase creates poly(A) tails on miRNAs hybridized onto locked nucleic acid (LNA) microarrays. DNA-modified nanoparticles are then adsorbed onto the poly(A) tails and detected with SPRI. This ultrasensitive nanoparticle-amplified SPRI methodology can be used for miRNA profiling at attamole levels.

In certain embodiments, labels, dyes, or labeled probes and/or primers are used to detect amplified or unamplified miRNAs. The skilled artisan will recognize which detection methods are appropriate based on the sensitivity of the detection method and the abundance of the target. Depending on the sensitivity of the detection method and the abundance of the target, amplification may or may not be required prior to detection. One skilled in the art will recognize the detection methods where miRNA amplification is preferred.

A probe or primer may include standard (A, T or U, G and C) bases, or modified bases. Modified bases include, but are not limited to, the AEGIS bases (from Eragen Biosciences). In certain aspects, bases are joined by a natural phosphodiester bond or a different chemical linkage. Different chemical linkages include, but are not limited to, a peptide bond or a Locked Nucleic Acid (LNA) linkage.

In a further aspect, oligonucleotide probes or primers present in an amplification reaction are suitable for monitoring the amount of amplification product produced as a function of time. In certain aspects, probes having different single stranded versus double stranded character are used to detect the nucleic acid. Probes include, but are not limited to, the 5′-exonuclease assay (e.g., TaqMan™) probes, stem-loop molecular beacons, stemless or linear beacons, peptide nucleic acid (PNA) Molecular Beacons, linear PNA beacons, non-FRET probes, Sunrise™/AmplifluorB™ probes, stem-loop and duplex Scorpion™ probes, bulge loop probes, pseudo knot probes, cyclicons, MGB Eclipse™ probe (Epoch Biosciences), hairpin probes, PNA light-up probes, anti-primer quench probes, self-assembled nanoparticle probes, and ferrocene-modified probes.

In certain embodiments, one or more of the primers in an amplification reaction can include a label. In yet further embodiments, different probes or primers comprise detectable labels that are distinguishable from one another. In some embodiments a nucleic acid, such as the probe or primer, may be labeled with two or more distinguishable labels. In some aspects, a label is attached to one or more probes and has one or more of the following properties: (i) provides a detectable signal; (ii) interacts with a second label to modify the detectable signal provided by the second label, e.g., FRET (Fluorescent Resonance Energy Transfer); (iii) stabilizes hybridization, e.g., duplex formation; and (iv) provides a member of a binding complex or affinity set, e.g., affinity, antibody-antigen, ionic complexes, hapten-ligand (e.g. biotin-avidin). In still other aspects, use of labels can be accomplished using any one of a large number of known techniques employing known labels, linkages, linking groups, reagents, reaction conditions, and analysis and purification methods.

miRNAs can be detected by direct or indirect methods. In a direct detection method, one or more miRNAs are detected by a detectable label that is linked to a nucleic acid molecule. In such methods, the miRNAs may be labeled prior to binding to the probe. Therefore, binding is detected by screening for the labeled miRNA that is bound to the probe. The probe is optionally linked to a bead in the reaction volume.

In certain embodiments, nucleic acids are detected by direct binding with a labeled probe, and the probe is subsequently detected. In one embodiment of the invention, the nucleic acids, such as amplified miRNAs, are detected using FlexMAP Microspheres (Luminex) conjugated with probes to capture the desired nucleic acids. Some methods may involve detection with polynucleotide probes modified with fluorescent labels or branched DNA (bDNA) detection, for example.

In other embodiments, nucleic acids are detected by indirect detection methods. For example, a biotinylated probe may be combined with a streptavidin-conjugated dye to detect the bound nucleic acid. The streptavidin molecule binds a biotin label on amplified miRNA, and the bound miRNA is detected by detecting the dye molecule attached to the streptavidin molecule. In one embodiment, the streptavidin-conjugated dye molecule comprises Phycolink® Streptavidin R-Phycoerythrin (PROzyme). Other conjugated dye molecules are known to persons skilled in the art.

Labels include, but are not limited to: light-emitting, light-scattering, and light-absorbing compounds which generate or quench a detectable fluorescent, chemiluminescent, or bioluminescent signal. A dual labeled fluorescent probe that includes a reporter fluorophore and a quencher fluorophore is used in some embodiments. It will be appreciated that pairs of fluorophores are chosen that have distinct emission spectra so that they can be easily distinguished.

In certain embodiments, labels are hybridization-stabilizing moieties which serve to enhance, stabilize, or influence hybridization of duplexes, e.g., intercalators and intercalating dyes (including, but not limited to, ethidium bromide and SYBR-Green), minor-groove binders, and cross-linking functional groups.

In other embodiments, methods relying on hybridization and/or ligation to quantify miRNAs may be used, including oligonucleotide ligation (OLA) methods and methods that allow a distinguishable probe that hybridizes to the target nucleic acid sequence to be separated from an unbound probe. As an example, HARP-like probes may be used to measure the quantity of miRNAs. In such methods, after hybridization between a probe and the targeted nucleic acid, the probe is modified to distinguish the hybridized probe from the unhybridized probe. Thereafter, the probe may be amplified and/or detected. In general, a probe inactivation region comprises a subset of nucleotides within the target hybridization region of the probe. To reduce or prevent amplification or detection of a HARP probe that is not hybridized to its target nucleic acid, and thus allow detection of the target nucleic acid, a post-hybridization probe inactivation step is carried out using an agent which is able to distinguish between a HARP probe that is hybridized to its targeted nucleic acid sequence and the corresponding unhybridized HARP probe. The agent is able to inactivate or modify the unhybridized HARP probe such that it cannot be amplified.

A probe ligation reaction may also be used to quantify miRNAs. In a Multiplex Ligation-dependent Probe Amplification (MLPA) technique, pairs of probes which hybridize immediately adjacent to each other on the target nucleic acid are ligated to each other driven by the presence of the target nucleic acid. In some aspects, MLPA probes have flanking PCR primer binding sites. MLPA probes are specifically amplified when ligated, thus allowing for detection and quantification of miRNA biomarkers.

An miRNA expression profile may be calculated based on a sample from a subject. In some embodiments, the miRNA expression profile may be used to diagnosis prostate cancer and to evaluate its aggressiveness. In some implementations, a subject's miRNA expression profile may be used to predict biochemical recurrence after a first treatment for prostate cancer. For example, the profile may be used to predict recurrence after radical prostatectomy. In another implementation, a subject's miRNA expression profile may be used to predict biochemical recurrence after a second treatment for prostate cancer. For example, the profile may be used to predict recurrence after salvage radiation therapy. In other embodiments, an miRNA expression profile may be used to evaluate the effectiveness of a prostate cancer treatment regimen.

For example, in some embodiments, the profile includes miRNA-137, miRNA-1283, or a combination thereof. In some embodiments, the profile includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 of the miRNAs listed in Table 1. As disclosed herein, these miRNAs are deregulated in prostate cancer and may be used to diagnose prostate cancer. In particular, hsa-miR-205-5p, hsa-miR-1283, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-145-5p, hsa-miR-1253, hsa-miR-133a, hsa-miR-1, and hsa-miR-143-3p may be differentially expressed at least two-fold less in prostate cancer cells compared to epithelial cells; while hsa-miR-137 and hsa-miR-375 may be differentially expressed at least two-fold higher in prostate cancer cells compared to epithelial cells. In some embodiments, the method further comprises treating a subject having a profile indicative of prostate cancer. Treatment may include a biopsy to confirm the existence and aggressiveness of prostate cancer tumor.

TABLE 1 Eleven miRNAs differentially regulated in prostate tumor tissue as compared to the surrounding epithelial tissue. ratio: p-value: miRNA ID tumor versus epithelium tumor versus epithelium hsa-miR-205-5p 5.0 ↓ 0.0002 hsa-miR-1283 3.3 ↓ 0.0024 hsa-miR-221-3p 3.3 ↓ <.0001 hsa-miR-222-3p 2.5 ↓ <.0001 hsa-miR-145-5p 2.5 ↓ 0.0002 hsa-miR-1253 2.5 ↓ 0.0015 hsa-miR-133a 2.0 ↓ <.0001 hsa-miR-1 2.0 ↓ <.0001 hsa-miR-1 2.0 ↓ 0.0006 hsa-miR-137 2.1 ↑ 0.0173 hsa-miR-375 2.4 ↑ <.0001

One example implementation includes a method of using an miRNA expression profile to predict biochemical recurrence after radical prostatectomy. The profile may include at least one of the miRNAs listed in Table 2 including at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, or 88 of the miRNAs listed in Table 2. The miRNA expression profile may be used to calculate a recurrence risk score. In some cases, the recurrence risk score may be an indication of how soon recurrence will occur. A higher risk score may indicate that recurrence will occur at an earlier date than a lower risk score. A high recurrence risk may indicate a recurrence within 1-5 years after radical prostatectomy. In other implementations, a high recurrence risk indicates a recurrence within 2-4 years after the treatment. In still other implementations, a high recurrence risk indicates a recurrence within 36 months after radical prostatectomy. If a subject is found to have a high recurrence risk score, subsequent treatment options might include radiation therapy, adjuvant therapy, or in some cases, palliative care. If a subject is found to have a low recurrence risk score, subsequent treatment options may include continued clinical monitoring without radiation or adjuvant therapy.

TABLE 2 miRNAs that predict biochemical recurrence post-radical prostatectomy (RP) via multivariate Cox-regression analysis D′Amico Stephensen nomogram Stephensen nomogram nomogram (categorical) (continuous) Hazard Confidence Hazard Confidence Hazard Confidence miR_ID Ratio p-value Interval Ratio p-value Interval Ratio p-value Interval hsa-miR-107 3.69 0.0002 (1.9, 7.3) 3.42 0.0005 (1.7, 6.9) 3.37 0.0006 (1.7, 6.7) hsa-miR-98 3.49 0.0003 (1.8, 6.9) 2.37 0.0086 (1.2, 4.5) 2.44 0.0059 (1.3, 4.6) hsa-let-7a-5p 3.24 0.0006 (1.7, 6.4) 2.18 0.0188 (1.1, 4.2) 2.23 0.0156 (1.2, 4.3) hsa-miR-324-5p 3.03 0.0008 (1.6, 5.8) 3.08 0.0007 (1.6, 5.9) 2.92 0.0011 (1.5, 5.6) hsa-miR-1060-5p 3.02 0.0031 (1.5, 6.3) 2.95 0.005 (1.4, 6.3) 3.04 0.004 (1.4, 6.5) hsa-let-7f-5p 3.01 0.0013 (1.5, 5.9) 3.03 0.0017 (1.5, 6.1) 3.13 0.0011 (1.6, 6.2) hsa-let-7e-5p 3 0.0009 (1.6, 5.7) 2.22 0.044 (1.2, 4.2) 2.27 0.0106 (1.2, 4.3) hsa-miR-28-5p 2.97 0.0011 (1.5, 5.7) 2.5 0.0054 (1.3, 4.8) 2.51 0.0058 (1.3, 4.8) hsa-miR-29c-3p 2.94 0.0014 (1.5, 5.7) 3.04 0.0014 (1.5, 6)   2.86 0.0023 (1.5, 5.6) hsa-let-7g-5p 2.94 0.0016 (1.5, 5.7) 2.2 0.0162 (1.2, 4.2) 2.22 0.0136 (1.2, 4.2) hsa-miR-148a-3p 2.9 0.0032 (1.4, 5.9) 2.69 0.0071 (1.3, 5.5) 2.88 0.0036 (1.4, 5.9) hsa-miR-18b-5p 2.78 0.0025 (1.4, 5.4) 4.23 0.0001 (2.1, 8.7) 4.02 0.0002 (1.9, 8.4) hsa-miR-15a-5p 2.76 0.003 (1.4, 5.4) 2.88 0.0026 (1.4, 5.7) 2.91 0.0022 (1.5, 5.8) hsa-miR-106a-5p + 2.72 0.007 (1.3, 5.6) 2.79 0.0065 (1.3, 5.8) 2.69 0.0084 (1.3, 5.6) miR-17-5p hsa-miR-365a-3p 2.7 0.0055 (1.3, 5.4) 2.93 0.0027 (1.5, 5.9) 3.14 0.0013 (1.6, 6.3) hsa-miR-194-5p 2.68 0.0091 (1.3, 5.6) 2.49 0.0226 (1.1, 5.4) 2.52 0.0177 (1.2, 5.4) hsa-miR-4454 2.67 0.0061 (1.3, 5.4) 2.73 0.0057 (1.3, 5.6) 2.7 0.0059 (1.3, 5.5) hsa-miR-191-5p 2.67 0.004 (1.4, 5.2) 2.55 0.0079 (1.3, 5.1) 2.65 0.0051 (1.3, 5.2) hsa-miR-141-3p 2.64 0.007 (1.3, 5.3) 2.68 0.0071 (1.3, 5.5) 2.74 0.0055 (1.3, 5.6) hsa-miR-548aa 2.62 0.0048 (1.3, 5.1) 2.86 0.0063 (1.3, 6.1) 2.62 0.0069 (1.3, 5.3) hsa-miR-497-5p 2.61 0.0035 (1.4, 5)   2.2 0.0146 (1.2, 4.1) 2.12 0.0185 (1.1, 4)   hsa-miR-30c-5p 2.6 0.0035 (1.4, 4.9) 2.89 0.0014 (1.5, 5.5) 2.68 0.0025 (1.4, 5.1) hsa-miR-4448 2.58 0.0052 (1.3, 5)   2.6 0.0052 (1.3, 5.1) 2.35 0.0107 (1.2, 4.5) hsa-miR-548v 2.56 0.0074 (1.3, 5.1) 2.29 0.0158 (1.2, 4.5) 2.38 0.0129 (1.2, 4.7) hsa-miR-148b-3p 2.52 0.0087 (1.3, 5)   2.7 0.0063 (1.3, 5.5) 2.61 0.0079 (1.3, 5.3) hsa-miR-1260b 2.51 0.0072 (1.3, 4.9) 2.49 0.0158 (1.2, 5.2) 2.49 0.0109 (1.2, 5)   hsa-miR-375 2.5 0.0093 (1.3, 5)   2.22 0.038   (1, 4.7) 2.33 0.0262 (1.1, 4.9) hsa-miR-221-3p 2.5 0.0052 (1.3, 4.8) 2.63 0.0036 (1.4, 5)   2.65 0.0041 (1.4, 5.2) hsa-miR-423-5p 2.5 0.0101 (1.2, 5)   2.65 0.0073 (1.3, 5.4) 2.77 0.0044 (1.4, 5.6) hsa-miR-195-5p 2.46 0.005 (1.3, 4.6) 2.06 0.0251 (1.1, 3.9) 2.04 0.0242 (1.1, 3.8) hsa-miR-27b-3p 2.42 0.0067 (1.3, 4.6) 2.13 0.019 (1.1, 4)   2.03 0.026 (1.1, 3.8) hsa-miR-483-3p 2.42 0.0143 (1.2, 4.9) 2.33 0.0278 (1.1, 5)   2.4 0.0191 (1.2, 5)   hsa-miR-193a-5p 2.4 0.0101 (1.2, 4.7) 3.49 0.0006 (1.7, 7.1) 3.77 0.0004 (1.8, 7.9) hsa-miR-660-5p 2.38 0.0104 (1.2, 4.6) 3.39 0.001 (1.6, 7)   2.92 0.002 (1.5, 5.7) hsa-miR-374b-5p 2.37 0.0073 (1.3, 4.5) 1.96 0.0365   (1, 3.7) 1.93 0.037   (1, 3.6) hsa-miR-1206 2.36 0.0145 (1.2, 4.7) 2.29 0.0234 (1.1, 4.7) 2.33 0.0184 (1.2, 4.7) hsa-miR-30b-5p 2.32 0.0169 (1.2, 4.6) 3.64 0.0008 (1.7, 7.7) 3.03 0.0021 (1.5, 6.1) hsa-let-7d-5p 2.31 0.0089 (1.2, 4.3) 1.91 0.0438   (1, 3.6) 1.95 0.0354   (1, 3.6) hsa-miR-135a-5p 2.3 0.012 (1.2, 4.4) 2.03 0.0281 (1.1, 3.8) 2.15 0.0165 (1.2, 4)   hsa-miR-24-3p 2.3 0.0095 (1.2, 4.3) 2.05 0.0238 (1.1, 3.8) 1.98 0.0307 (1.1, 3.7) hsa-miR-199a-3p + 2.28 0.0101 (1.2, 4.3) 1.93 0.04   (1, 3.6) 1.94 0.0366   (1, 3.6) miR-199b hsa-miR-130a-3p 2.15 0.0164 (1.2, 4)   2.03 0.0288 (1.1, 3.8) 2.04 0.0254 (1.1, 3.8) hsa-miR-1915-3p 2.15 0.02 (1.1, 4.1) 2.46 0.0091 (1.3, 4.8) 2.12 0.0237 (1.1, 4)   hsa-miR-99b-5p 2.15 0.0198 (1.1, 4.1) 2.06 0.0305 (1.1, 4)   1.88 0.0479   (1, 3.5) hsa-miR-93-5p 2.11 0.0315 (1.1, 4.2) 2.68 0.0049 (1.3, 5.3) 2.45 0.0099 (1.2, 4.8) hsa-miR-30d-5p 2.1 0.0229 (1.1, 4)   2.35 0.0119 (1.2, 4.6) 2.36 0.008 (1.3, 4.4) hsa-miR-15b-5p 2.05 0.0347 (1.1, 4)   2.38 0.0132 (1.2, 4.7) 2.25 0.0178 (1.2, 4.4) hsa-miR-23b-3p 2 0.0303 (1.1, 3.7) 2 0.0318 (1.1, 3.8) 2.01 0.0286 (1.1, 3.7) hsa-miR-421 1.95 0.0393   (1, 3.7) 1.98 0.0393   (1, 3.8) 2.06 0.0265 (1.1, 3.9) hsa-miR-145-5p 1.88 0.0462   (1, 3.5) 2.49 0.0059 (1.3, 4.8) 2.49 0.0069 (1.3, 4.8) hsa-miR-548t-5p 0.53 0.0449 (0.3, 1)   0.35 0.0026 (0.2, 0.7) 0.39 0.0049 (0.2, 0.8) hsa-miR-1180 0.52 0.0464 (0.3, 1)   0.35 0.0028 (0.2, 0.7) 0.36 0.0044 (0.2, 0.7) hsa-miR-515-3p 0.52 0.0471 (0.3, 1)   0.51 0.0437 (0.3, 1)   0.5 0.0334 (0.3, 0.9) hsa-miR-508-5p 0.51 0.0365 (0.3, 1)   0.31 0.0012 (0.2, 0.6) 0.35 0.0021 (0.2, 0.7) hsa-miR-513a-3p 0.51 0.0428 (0.3, 1)   0.39 0.0064 (0.2, 0.8) 0.45 0.0169 (0.2, 0.9) hsa-miR-566 0.51 0.031 (0.3, 0.9) 0.42 0.013 (0.2, 0.8) 0.5 0.0282 (0.3, 0.9) hsa-miR-613 0.5 0.0363 (0.3, 1)   0.39 0.0059 (0.2, 0.8) 0.41 0.0088 (0.2, 0.8) hsa-miR-1200 0.5 0.0353 (0.3, 1)   0.38 0.0041 (0.2, 0.7) 0.35 0.0027 (0.2, 0.7) hsa-miR-762 0.49 0.0323 (0.3, 0.9) 0.3 0.001 (0.2, 0.6) 0.33 0.0021 (0.2, 0.7) hsa-miR-450b-3p 0.49 0.0324 (0.2, 0.9) 0.42 0.0113 (0.2, 0.8) 0.44 0.0149 (0.2, 0.9) hsa-miR-1205 0.48 0.021 (0.3, 0.9) 0.42 0.0139 (0.2, 0.8) 0.45 0.0136 (0.2, 0.9) hsa-miR-3168 0.48 0.0212 (0.3, 0.9) 0.38 0.0059 (0.2, 0.8) 0.4 0.0064 (0.2, 0.8) hsa-miR-548d-5p 0.47 0.0471 (0.2, 1)   0.45 0.0327 (0.2, 0.9) 0.41 0.0189 (0.2, 0.9) hsa-miR-320a 0.47 0.0271 (0.2, 0.9) 0.41 0.0095 (0.2, 0.8) 0.41 0.01 (0.2, 0.8) hsa-miR-3136-5p 0.47 0.0231 (0.2, 0.9) 0.47 0.0266 (0.2, 0.9) 0.45 0.0173 (0.2, 0.9) hsa-miR-3934 0.47 0.0166 (0.2, 0.9) 0.41 0.0058 (0.2, 0.8) 0.37 0.003 (0.2, 0.7) hsa-miR-409-3p 0.45 0.019 (0.2, 0.9) 0.41 0.01 (0.2, 0.8) 0.34 0.0032 (0.2, 0.7) hsa-miR-516a-3p 0.45 0.0216 (0.2, 0.9) 0.4 0.0089 (0.2, 0.8) 0.4 0.0074 (0.2, 0.8) hsa-miR-1288 0.45 0.0128 (0.2, 0.8) 0.5 0.034 (0.3, 0.9) 0.49 0.0282 (0.3, 0.9) hsa-miR-541-3p 0.44 0.0108 (0.2, 0.8) 0.41 0.006 (0.2, 0.8) 0.44 0.0101 (0.2, 0.8) hsa-miR-1257 0.44 0.025 (0.2, 0.9) 0.27 0.0005 (0.1, 0.6) 0.25 0.0005 (0.1, 0.5) hsa-miR-548ak 0.44 0.0139 (0.2, 0.8) 0.26 0.0003 (0.1, 0.5) 0.27 0.0004 (0.1, 0.6) hsa-miR-1323 0.44 0.0171 (0.2, 0.9) 0.45 0.02 (0.2, 0.9) 0.45 0.0232 (0.2, 0.9) hsa-miR-216a 0.41 0.0076 (0.2, 0.8) 0.24 0.0002 (0.1, 0.5) 0.34 0.0018 (0.2, 0.7) hsa-miR-922 0.41 0.0097 (0.2, 0.8) 0.3 0.0006 (0.1, 0.6) 0.32 0.0011 (0.2, 0.6) hsa-miR-302a-3p 0.41 0.0067 (0.2, 0.8) 0.36 0.0053 (0.2, 0.7) 0.39 0.0041 (0.2, 0.7) hsa-miR-1276 0.4 0.011 (0.2, 0.8) 0.35 0.0045 (0.2, 0.7) 0.35 0.0033 (0.2, 0.7) hsa-miR-34c-3p 0.4 0.0046 (0.2, 0.8) 0.36 0.0028 (0.2, 0.7) 0.4 0.0046 (0.2, 0.8) hsa-miR-572 0.39 0.0048 (0.2, 0.8) 0.25 0.0003 (0.1, 0.5) 0.35 0.0014 (0.2, 0.7) hsa-miR-1908 0.36 0.0029 (0.2, 0.7) 0.4 0.0098 (0.2, 0.8) 0.39 0.0067 (0.2, 0.8) hsa-miR-568 0.35 0.0026 (0.2, 0.7) 0.25 0.0001 (0.1, 0.5) 0.28 0.0003 (0.1, 0.6) hsa-miR-576-3p 0.35 0.0028 (0.2, 0.7) 0.27 0.0002 (0.1, 0.5) 0.28 0.0002 (0.1, 0.5) hsa-miR-486-3p 0.34 0.002 (0.2, 0.7) 0.28 0.0004 (0.1, 0.6) 0.29 0.0004 (0.1, 0.6) hsa-miR-638 0.33 0.001 (0.2, 0.6) 0.31 0.0005 (0.2, 0.6) 0.32 0.0007 (0.2, 0.6) hsa-miR-885-5p 0.31 0.0007 (0.2, 0.6) 0.44 0.0122 (0.2, 0.8) 0.42 0.007 (0.2, 0.8) hsa-miR-1286 0.31 0.0013 (0.1, 0.6) 0.33 0.0047 (0.2, 0.7) 0.3 0.0016 (0.1, 0.6) hsa-miR-450b-5p 0.28 0.0005 (0.1, 0.6) 0.33 0.0019 (0.2, 0.7) 0.31 0.001 (0.2, 0.6) hsa-miR-890 0.25 0.0001 (0.1, 0.5) 0.27 0.0006 (0.1, 0.6) 0.34 0.0025 (0.2, 0.7)

Another exemplary implementation includes a method of using a miRNA expression profile to predict biochemical recurrence after radiation therapy, such as salvage radiation therapy. The profile may include at least one of the miRNAs listed in Table 3, including at least 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the miRNAs listed in Table 3. In some embodiments, the profile may include at least miRNA-601 and miRNA-4516. The profile may be used alone or in conjunction with other prognostic parameters to calculate the recurrence risk score after radiation therapy. For example, the profile may be used in combination with the subject's age, Gleason score, tumor stage (pT), lymph node score (pN), PSA levels, resection status, D'Amico classification, Stephenson nomograms, or any combination thereof to calculate the recurrent risk score. In some cases, the recurrence risk score may be an indication of how soon recurrence may occur. For example, a high recurrence risk may indicate a recurrence within 1-5 years after radiation therapy. In other implementations, a high recurrence risk indicates a recurrence within 2-4 years after the treatment. In still other implementations, a high recurrence risk indicates a recurrence within 36 months after radiation therapy. If a subject is found to have a high recurrence risk score, subsequent treatment options might include radical prostatectomy, adjuvant therapy, or in some cases, palliative care. If a subject is found to have a low recurrence risk score, subsequent treatment options might include continued clinical monitoring without radical prostatectomy or radical prostatectomy with clinical monitoring.

TABLE 3 Nine miRNAs predictive of biochemical recurrence after salvage radiation therapy. hazard ratio miRNA ID (high versus low) p-value Confidence interval hsa-miR-628-3p 6.6 0.0036 1.9-23.5 hsa-miR-1193 5 0.0064 1.6-15.6 hsa-miR-601 4.6 0.0037 1.6-12.7 hsa-miR-4516 3.6 0.0128 1.3-10 hsa-miR-320e 3.7 0.0339 1.1-9.6 hsa-miR-508-3p 3 0.0296 1.1-8 hsa-miR-598 0.3 0.0304 0.1-0.9 hsa-miR-626 0.3 0.0391 0.1-0.9 hsa-miR-563 0.3 0.0228 0.1-0.8

Recurrence risk scores after radical prostatectomy or radiation therapy or can be calculated using standard mathematical methods, models, and algorithms. In some embodiments, the risk score is a regression value, e.g., where a regression value of about 1 is an indication of recurrence. For example, the miRNA profile may be analyzed by multivariate regression analysis (e.g., determined by linear regression), a Cox regression model, or principal component analysis to derive a risk score. In other implementations, the miRNA profile or levels of specific miRNA biomarkers may be used in conjunction with other factors (for example, age, PSA levels, pathologic tumor (pT) and lymph node (pN) classification, Gleason score, resection status, D'Amico classification, and/or Stephenson nomograms) to calculate a recurrence risk score. For example, the miRNA profile may be used with other factors to create nomograms for predicting the recurrence risk score. In still other implementations, specific miRNA biomarkers are used to calculate the recurrence risk score. For example, in some embodiments, levels of miRNA relative to control values are negatively/positively correlated to risk score.

In some embodiments, miRNA panels contain numerous data points that are best managed and stored in a computer readable form. Therefore, in preferred embodiments, the risk score is a regression value derived from the miRNA panels as a weighted function of the quantified miRNA. The weighted function can be derived from linear regression analysis of experimental results comparing miRNA of normal subjects versus those with prostate cancer and/or biochemical recurrence. Each miRNA species can be multiplied by a weighting constant and summed.

Generally speaking, a regression value is a single value that is sensitive to changes in abundance of miRNA species of a miRNA profile, with a regression value of about 1 being indicative of a high risk of recurrence. For example, a regression value of about 0 can be indicative of low risk of recurrence, while a regression value of about 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, and more may be indicative of high risk of recurrence

Prior to analysis, the data in each dataset can be collected by measuring the values for each miRNA biomarker, usually in duplicate or triplicate or in multiple replicates. The data may be manipulated, for example raw data may be transformed using standard curves, and the average of replicate measurements used to calculate the average and standard deviation for each patient. These values may be transformed before being used in the models, e.g. log-transformed, Box-Cox transformed, etc. This data can then be input into an analytical process with defined parameter.

The analytic classification process may be any type of learning algorithm with defined parameters, or in other words, a predictive model. In general, the analytical process will be in the form of a model generated by a statistical analytical method such as those described below. Examples of such analytical processes may include a linear algorithm, a quadratic algorithm, a polynomial algorithm, a decision tree algorithm, or a voting algorithm. Using any suitable learning algorithm, an appropriate reference or training dataset can be used to determine the parameters of the analytical process to be used for classification, i.e., develop a predictive model. The reference or training dataset to be used will depend on the desired classification to be determined. The dataset may include data from two, three, four or more classes.

The number of features that may be used by an analytical process to classify a test subject with adequate certainty is 2 or more. In some embodiments, it is 3 or more, 4 or more, 10 or more, or between 10 and 200. Depending on the degree of certainty sought, however, the number of features used in an analytical process can be more or less, but in all cases is at least 2. In one embodiment, the number of features that may be used by an analytical process to classify a test subject is optimized to allow a classification of a test subject with high certainty.

Suitable data analysis algorithms are known in the art. In one embodiment, a data analysis algorithm of the disclosure comprises Classification and Regression Tree (CART), Multiple Additive Regression Tree (MART), Prediction Analysis for Microarrays (PAM), or Random Forest analysis. Such algorithms classify complex spectra from biological materials, such as a blood sample, to distinguish subjects as normal or as possessing biomarker levels characteristic of a particular condition (e.g., biochemical recurrence). In other embodiments, a data analysis algorithm of the disclosure comprises ANOVA and nonparametric equivalents, linear discriminant analysis, logistic regression analysis, nearest neighbor classifier analysis, neural networks, principal component analysis, hierarchical cluster analysis, quadratic discriminant analysis, regression classifiers and support vector machines.

As will be appreciated by those of skill in the art, a number of quantitative criteria can be used to communicate the performance of the comparisons made between a test marker profile and reference marker profiles. These include area under the curve (AUC), hazard ratio (HR), relative risk (RR), reclassification, positive predictive value (PPV), negative predictive value (NPV), accuracy, sensitivity and specificity, Net reclassification Index, Clinical Net reclassification Index. In addition, other constructs such a receiver operator curves (ROC) can be used to evaluate analytical process performance.

The predicted risk of recurrence can be used to select an appropriate therapy and further treat the subject. The term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. The term “treatment” therefore includes clinical intervention to alter or prevent the development or spread of prostate cancer. Treatment may include surgical approaches, radiation therapies, adjuvant therapies, or ultrasound treatments, alone or in any combination. Surgical therapies or treatments may include cryosurgery, orchiectomy, or prostatectomy. Prostatectomy may include removal of part or all of the prostate gland. Radical prostatectomy includes removal of all of the prostate gland, the seminal vesicles, the nearby tissue, and the nearby lymph nodes. The method of prostatectomy may be retropubic, suprapubic, perineal, minimally-invasive, nerve-sparing, laparoscopic, or robotic-assisted.

Radiation therapies or treatments may include external beam radiation therapy or internal radiation therapy. External beam radiation therapy may include three-dimensional conformal radiation therapy, intensity modulated radiation therapy, stereotactic body radiation therapy, or protein beam radiation therapy. Internal radiation therapy (or brachytherapy) may include permanent or temporary approaches. As used herein, salvage radiation therapy is radiation treatment that occurs after a first round of treatment for prostate cancer.

Adjuvant therapies or treatments may include chemotherapy, hormone therapy, biologic therapy (including immunotherapy), radiation therapy or targeted therapy. Chemotherapeutic treatments may include administration of Docetaxel (Taxotere®), Cabazitaxel (Jevtana®), Mitoxantrone (Novantrone®), Estramustine (Emcyt®), Doxorubicin (Adriamycin®), Etoposide (VP-16), Vinblastine (Velban®), Paclitaxel (Taxol®), Carboplatin (Paraplatin®), or Vinorelbine (Navelbine®), alone or in any combination. Hormone therapies may include luteinizing hormone-releasing hormone agonists, luteinizing hormone-releasing hormone antagonists, CYP17 inhibitors, anti-androgens, or estrogens.

Also disclosed is a kit for predicting biochemical recurrence after radical prostatectomy. The kit may include a panel of oligonucleotides configured to bind to a group of miRNAs consisting of those listed in Table 2. Also disclosed is a kit for predicting biochemical recurrence after radiation treatment or therapy. The kit may include a panel of oligonucleotides configured to bind to a group of miRNAs consisting of those listed in Table 3.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

EXAMPLE Example 1: An miRNA-Based Predictive Model for Biochemical Recurrence Following Post-Prostatectomy Salvage Radiation Therapy

Materials and Methods

Patient Cohort.

FFPE blocks from 43 patients with PCa who had undergone RP (1997-2009) followed by salvage RT between 2005 and 2011 at the University of Freiburg, Germany, were used in this study. A flow chart of the study design can be found in FIG. 6. Patients who received adjuvant RT (RT initiated less than 6 months after RP) were excluded from the analysis. Follow-up time after RT was defined to be greater than 4 years. A clinical database was established which contained patient characteristics, tumor classification according to the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) 2010 TNM system due to the dates of the earliest radical prostatectomies in the study, tumor grading according to Gleason score without inclusion of tertiary score, radiation treatment details including toxicities, and follow-up details including PSA concentrations. There were no significant differences in terms of radiation techniques, planning target volume generation, doses and radiation volumes in the cohort. All patients were treated 1.8-2.0 Gy per fraction to a total dose of 66.6-74 Gy. Use of hormone therapy and whole pelvis radiation was at the discretion of the treating physician. Recurrence was defined as either biochemical failure (BF) with a rise of PSA≧0.2 ng/ml at least twice as per the AUA recommendation or clinical progression with local (prostatic fossa), regional (lymph nodes) or distant (metastasis) recurrence. Imaging tests (CT, PET/CT or bone scan) were done when clinically indicated in cases of BF.

Ethics Statement.

This study was approved by both the Medical Center University Freiburg and The Ohio State University institutional review boards with waived patient consent due to the archival nature of the study. In addition, data and tissue samples pertaining to this study were de-identified prior to analysis.

Sample Processing & RNA Isolation.

All formalin-fixed, paraffin-embedded (FFPE) blocks were reviewed by the same pathologist specialized in genitourinary diseases and Gleason scores were reassessed for each core using the ISUP 2005 grading system (Epstein et al., American Journal of Surgical Pathology, 2005). Tissue samples from the Medical Center University of Freiburg pathology tissue bank were obtained which included tissue from prostate tumor, non-neoplastic prostate epithelium, and non-neoplastic prostate stroma. Areas of interest were marked on an H&E stained slide and 1-mm diameter biopsy cores were punched from each area of interest. Cores from tumor were taken from the area with the highest Gleason Score and were enriched for tumor (>70/o).

Total RNA was isolated using a combination of RecoverAll Total Nucleic Acid Isolation digestion buffer, AM1975, (Life Technologies; Carlsbad, Calif.) with Qiagen FFPE miRNeasy kit, Cat. #217504 (Qiagen; Venlo, Limburg). In brief, cores were digested overnight using RecoverAll Total Nucleic Acid Isolation digestion buffer and proteinase K leading to enhanced digestion of the core. Once cores were digested (next day), the Qiagen FFPE miRNeasy manual was followed starting at the 80° C. for 15 minute incubation. RNA concentrations were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific; Waltham, Mass.).

miRNA4 Expression Analysis.

For miRNA expression data generation, the NanoString human v2 array, which contains 800 miRNA probes, was used. Forty three tumor, 31 epithelium, and 21 stroma samples were analyzed. Expression analysis was conducted at The Ohio State University Nucleic Acid Core Facility (Columbus, Ohio). A total of 100 ng RNA input was used per sample and conditions were set according to the manufacturer's recommended protocol (NanoString Technologies; Seattle, Wash.). miRNAs were quantified using the nCounter Digital Analyzer as counts. miRNAs were filtered out from downstream analysis if total counts were less than 32 across 90% of the samples. Four hundred and seventy seven miRs were left after the filtering. Data were normalized by the geometric mean of all targets using the nSolver software (NanoString Technologies; Seattle, Wash.).

Statistical Analysis.

For tissue specific comparisons, 31 matched tumor and epithelium, 21 matched tumor and stroma, and 21 epithelium and stroma pairs were used. Normalized NanoString data were analyzed using Analysis of variance (ANOVA) with repeated measures method. A pairwise comparison was used to determine expression differences between tumor, stroma and epithelium.

To compare the difference in miRNA expression between late and early time to first biochemical recurrence post-RP (36 months as a cutoff) or between the time to the recurrence post-salvage RT, 2-sample t-tests were used. For each miRNA, patients were dichotomized into high and low groups based on the median miRNA expression and the difference in the probabilities of the time to the recurrence (post-RP or post-salvage RT recurrence) were compared using the log-rank test for each miRNA. Multivariate analyses were performed using COX proportional hazard regression models. ROC curve analysis was performed to determine the capability and cut-off level of variables that distinguished between the recurrence and non-recurrence of post-salvage RT. All analyses were performed using SAS 9.3 (SAS, Inc; Cary, N.C.) or R 3.0.

Results

Prostate Issue-Specific miRNA Expression Profiles.

In order to validate known miRNAs and identify novel miRNAs differentially regulated in prostate tumor tissue and adjacent tissues, expression data from tumor tissue (n=43) benign epithelium (n=31) and stroma (n=21) of 43 evaluable patients were analyzed using NanoString technology. As shown in Table 4, 45 miRNAs were significantly differentially expressed 1.5-fold or greater in tumor compared to epithelium; of those 11 were differentially expressed greater than 2-fold (p-value<0.05) (Table 1). One hundred and eight miRNAs were significantly differentially expressed greater than 1.5-fold in tumor when compared with stroma and of those miRNAs, 27 were differentially expressed 2-fold or more (p-value<0.05) (Table 4). Comparing epithelium and stroma samples, 84 miRNAs were significantly differentially expressed greater than 1.5-fold and of those miRNAs, 24 were differentially expressed 2-fold or more (ANOVA, p-value<0.05) (Table 4). Of the miRNAs significantly differentially expressed 1.5-fold or greater between all tissues types, 330 miRNAs were similar among all comparisons (FIG. 1).

TABLE 4 Comparison of miRNA expression levels from tumor tissue, epithelium, and stroma p- p- p- Ratio: value: Ratio: value: Ratio: value: Tu vs Tu vs Tu vs Tu vs Ep vs Ep vs miR_ID Ep Ep miR_ID St St miR_ID St St hsa-miR-205-5p 0.19748 0.0002 hsa-miR-204-5p 0.30722 <.0001 hsa-miR-4508 0.3007 <.0001 hsa-miR-1283 0.26303 0.0024 hsa-miR-221-3p 0.33791 <.0001 hsa-miR-4425 0.3839 <.0001 hsa-miR-221-3p 0.34003 <.0001 hsa-miR-222-3p 0.3428 <.0001 hsa-miR-548al 0.3959 <.0001 hsa-miR-222-3p 0.35894 <.0001 hsa-miR-143-3p 0.35346 <.0001 hsa-miR-454-3p 0.4133 <.0001 hsa-miR-145-5p 0.40273 0.0002 hsa-miR-23b-3p 0.38186 <.0001 hsa-miR-548p 0.4279 <.0001 hsa-miR-1253 0.4223 0.0015 hsa-miR-145-5p 0.38408 0.0005 hsa-miR-516a- 0.431 <.0001 5p hsa-miR-133a 0.48172 <.0001 hsa-miR-1 0.40192 <.0001 hsa-miR-370 0.4452 <.0001 hsa-miR-1 0.49242 <.0001 hsa-miR-133a 0.43283 <.0001 hsa-miR-219-1- 0.4564 <.0001 3p hsa-miR-143-3p 0.49585 0.0006 hsa-miR-199a- 0.43876 <.0001 hsa-miR-1185- 0.4752 <.0001 3p?miR-199b- 5p hsa-miR-549 0.50386 0.0011 hsa-miR-454-3p 0.45904 <.0001 hsa-miR-424-5p 0.4819 <.0001 hsa-miR-204-5p 0.50859 <.0001 hsa-miR-455-3p 0.45906 <.0001 hsa-miR-325 0.4957 <.0001 hsa-miR-130a- 0.51 <.0001 hsa-miR-214-3p 0.46623 <.0001 hsa-miR-455-3p 0.5222 <.0001 3p hsa-miR-27b-3p 0.51173 0.0003 hsa-miR-516a- 0.46797 <.0001 hsa-miR-23c 0.5531 <.0001 5p hsa-miR-378e 0.5256 0.0022 hsa-miR-130a- 0.47211 <.0001 hsa-miR-4284 0.5584 <.0001 3p hsa-miR-100-5p 0.52834 <.0001 hsa-miR-27b-3p 0.47864 0.0004 hsa-miR-606 0.5637 <.0001 hsa-miR-23b-3p 0.52907 0.0003 hsa-let-7e-5p 0.48272 <.0001 hsa-miR-342-5p 0.5668 0.0025 hsa-miR-22-3p 0.55427 <.0001 hsa-miR-34a-5p 0.49571 <.0001 hsa-miR-548aj- 0.5704 <.0001 3p hsa-miR-199a- 0.55888 <.0001 hsa-miR-4508 0.50746 <.0001 hsa-miR-208a 0.5787 <.0001 5p hsa-let-7e-5p 0.56457 0.0001 hsa-miR-205-5p 0.52804 0.1611 hsa-miR-495 0.589 <.0001 hsa-miR-455-5p 0.56705 <.0001 hsa-miR-23a-3p 0.53566 0.0003 hsa-miR-654-3p 0.5903 <.0001 hsa-miR-181a- 0.56875 <.0001 hsa-miR-152 0.53615 <.0001 hsa-miR-384 0.5913 <.0001 5p hsa-miR-34a-5p 0.61779 <.0001 hsa-miR-342-5p 0.5428 0.0006 hsa-miR-665 0.5983 <.0001 hsa-miR-99b-5p 0.61884 <.0001 hsa-miR-424-5p 0.55591 <.0001 hsa-miR-517a- 0.6028 <.0001 3p hsa-miR-125b- 0.62136 0.0011 hsa-miR-370 0.5609 <.0001 hsa-miR-204-5p 0.6041 0.0105 5p hsa-miR-99a-5p 0.62307 0.0014 hsa-miR-127-3p 0.56517 <.0001 hsa-miR-323a- 0.6054 <.0001 3p hsa-miR-126-3p 0.62482 0.002 hsa-miR-29b-3p 0.56706 0.0017 hsa-miR-615-5p 0.6125 0.0007 hsa-miR-23a-3p 0.63183 0.0022 hsa-miR-125b- 0.56976 0.0007 hsa-miR-127-3p 0.6199 <.0001 5p hsa-miR-199a- 0.6353 0.0045 hsa-miR-23c 0.57329 <.0001 hsa-miR-659-3p 0.6211 <.0001 3p?miR-199b- hsa-miR-542-5p 0.64145 0.0001 hsa-miR-548al 0.58235 <.0001 hsa-miR-16-5p 0.6262 0.0075 hsa-miR-223-3p 0.65116 0.0055 hsa-miR-219-1- 0.58486 <.0001 hsa-miR-1277- 0.6276 <.0001 3p 3p hsa-miR-30c-5p 0.65141 0.0039 hsa-miR-1233 0.58704 <.0001 hsa-miR-580 0.6333 <.0001 hsa-miR-24-3p 0.65778 0.0064 hsa-miR-100-5p 0.59362 0.0018 hsa-miR-3184- 0.6376 <.0001 5p hsa-miR-593-3p 0.66992 0.0005 hsa-miR-4425 0.5989 0.0004 hsa-miR-301a- 0.6538 0.0002 3p hsa-miR-548aa 0.6759 0.0093 hsa-miR-99b-5p 0.5999 <.0001 hsa-miR-342-3p 0.6675 0.0081 hsa-miR-214-3p 0.67866 0.0001 hsa-miR-542-5p 0.60152 <.0001 hsa-miR-658 0.6708 0.0002 hsa-miR-338-3p 0.68031 <.0001 hsa-miR-455-5p 0.60434 <.0001 hsa-miR-532-5p 0.6751 0.075 hsa-miR-125a- 0.69004 0.002 hsa-miR-208a 0.60571 <.0001 hsa-miR-362-3p 0.686 0.0014 5p hsa-miR-136-5p 0.69037 0.0003 hsa-miR-29a-3p 0.60724 0.0015 hsa-miR-214-3p 0.687 0.0014 hsa-miR-3195 0.70188 0.0401 hsa-miR-338-3p 0.61242 <.0001 hsa-miR-2682- 0.6889 0.0002 5p hsa-miR-218-5p 0.7088 0.0005 hsa-miR-199a- 0.61379 0.001 hsa-miR-199a- 0.6906 0.0481 5p 3p?miR-199b- hsa-miR-597 0.71327 <.0001 hsa-miR-342-3p 0.61403 0.0009 hsa-miR-4458 0.6912 0.0089 hsa-miR-1276 0.71574 0.0559 hsa-miR-495 0.61987 <.0001 hsa-miR-423-5p 0.6914 <.0001 hsa-miR-365a- 0.71864 0.0043 hsa-miR-28-5p 0.62129 0.0001 hsa-miR-9-5p 0.6943 0.0043 3p hsa-miR-1972 0.72462 0.2171 hsa-miR-548p 0.62147 0.0001 hsa-miR-656 0.6953 0.0001 hsa-miR-29b-3p 0.73214 0.0447 hsa-miR-218-5p 0.62385 <.0001 hsa-miR-152 0.6982 0.0019 hsa-miR-2054 0.73497 0.0077 hsa-miR-136-5p 0.62575 <.0001 hsa-miR-548a- 0.708 <.0001 3p hsa-let-7c 0.7384 0.025 hsa-miR-24-3p 0.6271 0.0071 hsa-miR-26a-5p 0.7113 0.1328 hsa-miR-187-3p 0.73981 0.0021 hsa-miR-99a-5p 0.62879 0.005 hsa-miR-518c- 0.7113 0.0034 3p hsa-let-7f-5p 0.75246 0.0538 hsa-let-7g-5p 0.63233 0.0044 hsa-miR-143-3p 0.7128 0.1438 hsa-miR-199b- 0.753 0.07 hsa-miR-325 0.63463 0.0002 hsa-miR-628-3p 0.7149 0.0004 5p hsa-miR-376c 0.75684 0.0012 hsa-miR-384 0.63628 <.0001 hsa-miR-140-3p 0.7178 0.0241 hsa-let-7i-5p 0.75956 0.0196 hsa-miR-665 0.64696 <.0001 hsa-miR-515-5p 0.7197 0.0024 hsa-miR-497-5p 0.76253 0.0381 hsa-miR-126-3p 0.65011 0.0111 hsa-miR-518b 0.7205 0.0008 hsa-miR-4454 0.76289 0.0449 hsa-miR-301a- 0.65348 <.0001 hsa-miR-23b-3p 0.7217 0.1064 3p hsa-miR-1264 0.76687 0.0017 hsa-let-7i-5p 0.65827 0.0021 hsa-miR-769-5p 0.7223 0.0037 hsa-miR-152 0.76791 0.0057 hsa-miR-150-5p 0.65898 0.0402 hsa-miR-423-3p 0.725 <.0001 hsa-miR-4532 0.76849 0.041 hsa-let-7c 0.65939 0.0071 hsa-miR-4443 0.7266 0.0443 hsa-miR-548n 0.76868 0.0007 hsa-miR-16-5p 0.66035 0.0115 hsa-miR-761 0.7302 0.0293 hsa-miR-376a- 0.76928 0.0259 hsa-miR-22-3p 0.66408 0.0093 hsa-miR-548ad 0.7314 <.0001 3p hsa-miR-29a-3p 0.76964 0.0511 hsa-miR-323a- 0.66624 <.0001 hsa-miR-182-5p 0.735 0.0253 3p hsa-miR-1233 0.77009 0.0143 hsa-miR-186-5p 0.66711 0.0004 hsa-miR-598 0.7374 0.0212 hsa-miR-331-5p 0.77148 0.0013 hsa-miR-199b- 0.66732 0.0235 hsa-miR-33a-5p 0.7449 0.0004 5p hsa-miR-935 0.77435 0.0088 hsa-let-7d-5p 0.66936 0.0013 hsa-miR-891b 0.7495 0.0033 hsa-miR-98 0.77954 0.0489 hsa-miR-187-3p 0.67114 0.0004 hsa-miR-1231 0.7539 0.0025 hsa-miR-3185 0.78001 0.0014 hsa-miR-548aj- 0.68079 0.0003 hsa-miR-450b- 0.7555 0.0033 3p 5p hsa-miR-150-5p 0.78714 0.1781 hsa-miR-193a- 0.68614 0.0002 hsa-miR-1908 0.757 0.0211 5p hsa-miR-450a- 0.7886 0.005 hsa-miR-769-5p 0.68692 0.0005 hsa-miR-1233 0.7623 0.0325 5p hsa-let-7g-5p 0.79354 0.0952 hsa-miR-1185- 0.6921 0.0008 hsa-miR-3934 0.7638 0.0029 5p hsa-miR-574-5p 0.79496 0.0731 hsa-miR-1277- 0.69368 0.0002 hsa-miR-1827 0.7688 0.0028 3p hsa-miR-1279 0.79531 0.0037 hsa-miR-125a- 0.69606 0.0069 hsa-miR-626 0.7695 0.0368 5p hsa-miR-4647 0.79609 0.0019 hsa-miR-140-3p 0.70238 0.0113 hsa-miR-432-5p 0.77 0.0038 hsa-miR-1180 0.79817 0.0066 hsa-miR-26a-5p 0.70328 0.0999 hsa-miR-28-5p 0.7729 0.0361 hsa-miR-548ah- 0.80004 0.0272 hsa-miR-30c-5p 0.70347 0.0324 hsa-miR-1303 0.7743 0.293 5p hsa-miR-155-5p 0.80335 0.0058 hsa-miR-1231 0.7152 0.0002 hsa-miR-29b-3p 0.7745 0.1657 hsa-miR-28-5p 0.80389 0.0333 hsa-miR-365a- 0.71628 0.01 hsa-let-7d-5p 0.7748 0.047 3p hsa-miR-548ab 0.80432 0.143 hsa-miR-891b 0.7167 0.0004 hsa-miR-2276 0.7748 0.0048 hsa-miR-548d- 0.80626 0.0652 hsa-miR-324-5p 0.72099 0.0018 hsa-miR-3180 0.7751 0.0098 3p hsa-miR-548q 0.8071 0.0243 hsa-miR-30a-5p 0.7224 0.0103 hsa-miR-508-5p 0.776 0.0179 hsa-miR-324-5p 0.808 0.0191 hsa-miR-2682- 0.72275 0.0005 hsa-miR-938 0.7777 0.0008 5p hsa-miR-18b-5p 0.80887 0.0466 hsa-miR-4443 0.72908 0.0351 hsa-miR-568 0.7787 0.0289 hsa-miR-2117 0.81113 0.0056 hsa-miR-615-5p 0.73109 0.0178 hsa-miR-663a 0.7796 0.0344 hsa-miR-193a- 0.8171 0.0194 hsa-miR-451a 0.73252 0.2396 hsa-miR-451a 0.7819 0.3798 5p hsa-miR-135b- 0.81825 0.0265 hsa-miR-519b- 0.73405 0.0012 hsa-miR-425-5p 0.7833 0.0161 5p 5p?miR-519c- hsa-miR-378a- 0.82024 0.043 hsa-miR-628-3p 0.73439 0.0005 hsa-miR-1208 0.7839 0.0026 3p?miR-3781 hsa-miR-181c- 0.82102 0.0326 hsa-miR-517a- 0.73463 0.0049 hsa-miR-590-5p 0.7843 0.0008 5p 3p hsa-miR-144-3p 0.82476 0.1619 hsa-miR-656 0.74057 0.0006 hsa-miR-140-5p 0.7862 0.0723 hsa-miR-4741 0.8292 0.0026 hsa-miR-525-3p 0.74313 0.0009 hsa-miR-186-5p 0.7866 0.0393 hsa-miR-496 0.83049 0.012 hsa-miR-193b- 0.74989 0.0162 hsa-miR-450b- 0.7866 0.0555 3p 3p hsa-miR-572 0.83232 0.0326 hsa-miR-518b 0.75744 0.0023 hsa-miR-29a-3p 0.789 0.1379 hsa-miR-374b- 0.83109 0.1435 hsa-miR-548ad 0.75989 0.0002 hsa-miR-15b-5p 0.7922 0.0906 5p hsa-miR-2116- 0.83417 0.152 hsa-let-7f-5p 0.76069 0.099 hsa-miR-647 0.7938 0.0128 5p hsa-miR-411-5p 0.83444 0.0047 hsa-miR-4532 0.76287 0.0621 hsa-miR-563 0.7944 0.0704 hsa-miR-485-3p 0.83546 0.0342 hsa-miR-219-5p 0.76613 0.0009 hsa-miR-374a- 0.7953 0.1439 5p hsa-miR-500a- 0.83688 0.0032 hsa-miR-98 0.76711 0.0629 hsa-miR-525-3p 0.7954 0.0133 5p?miR-501-5 hsa-miR-381 0.83799 0.0095 hsa-miR-654-3p 0.76727 0.0127 hsa-miR-564 0.7965 0.014 hsa-miR-483-3p 0.84189 0.0352 hsa-miR-376c 0.76883 0.0061 hsa-let-7g-5p 0.7969 0.17 hsa-miR-514a- 0.84402 0.0197 hsa-miR-27a-3p 0.76885 0.0052 hsa-miR-330-5p 0.7973 0.0061 3p hsa-miR-26b-5p 0.84428 0.1897 hsa-miR-658 0.77687 0.0105 hsa-miR-132-3p 0.7975 0.0429 hsa-miR-1260b 0.84432 0.0971 hsa-miR-876-3p 0.78233 0.0078 hsa-miR-448 0.7978 0.0094 hsa-miR-337-5p 0.84565 0.0224 hsa-miR-518c- 0.78329 0.0234 hsa-miR-499a- 0.7991 0.037 3p 3p hsa-miR-1268b 0.84788 0.0528 hsa-miR-423-5p 0.78341 0.0023 hsa-miR-519b- 0.7994 0.0234 5p?miR-519c- hsa-miR-186-5p 0.84807 0.0874 hsa-miR-548a- 0.78351 0.0012 hsa-miR-34a-5p 0.8024 0.0925 3p hsa-miR-1228- 0.8511 0.0225 hsa-miR-450a- 0.78371 0.0102 hsa-miR-4455 0.8128 0.0184 3p 5p hsa-miR-302a- 0.85302 0.0611 hsa-miR-3180 0.78474 0.0091 hsa-miR-302e 0.813 0.0072 3p hsa-miR-193b- 0.85351 0.1281 hsa-miR-574-3p 0.78502 0.0036 hsa-miR-1 0.8162 0.2971 3p hsa-miR-30a-5p 0.85415 0.1501 hsa-miR-329 0.78556 0.0068 hsa-miR-566 0.8177 0.0085 hsa-miR-542-3p 0.85423 0.0159 hsa-miR-409-3p 0.78858 0.0009 hsa-miR-1226- 0.8199 0.0388 3p hsa-miR-1322 0.85552 0.242 hsa-miR-626 0.79136 0.0473 hsa-miR-362-5p 0.8234 0.0287 hsa-miR-4488 0.85664 0.2798 hsa-miR-423-3p 0.79275 0.0002 hsa-miR-614 0.8235 0.0899 hsa-miR-31-5p 0.85829 0.0339 hsa-miR-761 0.79752 0.0928 hsa-miR-203 0.8272 0.1033 hsa-miR-616-3p 0.86079 0.0899 hsa-miR-26b-5p 0.79835 0.1237 hsa-miR-194-5p 0.8291 0.0232 hsa-miR-299-3p 0.86189 0.1465 hsa-miR-3184- 0.80096 0.017 hsa-miR-1909- 0.8297 0.0583 5p 3p hsa-miR-548y 0.86239 0.2626 hsa-miR-606 0.80164 0.0596 hsa-miR-876-3p 0.8298 0.0528 hsa-miR-942 0.86319 0.0639 hsa-miR-140-5p 0.80273 0.0811 hsa-miR-1234 0.8304 0.196 hsa-miR-621 0.86382 0.0223 hsa-miR-580 0.80698 0.0285 hsa-miR-941 0.8306 0.0151 hsa-let-7d-5p 0.86396 0.1677 hsa-miR-548z 0.80723 0.0725 hsa-miR-137 0.8309 0.6049 hsa-miR-1183 0.8664 0.1806 hsa-miR-564 0.80728 0.0141 hsa-miR-449c- 0.8309 0.0176 5p hsa-miR-142-3p 0.86645 0.4337 hsa-miR-432-5p 0.80804 0.0113 hsa-miR-766-3p 0.8321 0.0305 hsa-miR-181b- 0.86658 0.0456 hsa-miR-502-3p 0.8096 0.027 hsa-miR-654-5p 0.8324 0.0387 5p?miR-181d hsa-miR-550b- 0.87051 0.0826 hsa-miR-2276 0.81166 0.0133 hsa-miR-150-5p 0.8372 0.4019 3p hsa-miR-382-5p 0.87084 0.0517 hsa-miR-181a- 0.81425 0.1639 hsa-miR-1539 0.8377 0.0301 5p hsa-miR-3123 0.87195 0.0998 hsa-miR-330-5p 0.81446 0.0082 hsa-miR-193a- 0.8397 0.0877 5p hsa-miR-888-5p 0.87198 0.2774 hsa-miR-181c- 0.81462 0.0485 hsa-miR-582-5p 0.8397 0.193 5p hsa-miR-644a 0.87422 0.0368 hsa-miR-374a- 0.81635 0.1688 hsa-miR-548z 0.8409 0.168 5p hsa-miR-489 0.8745 0.0665 hsa-miR-659-3p 0.82019 0.032 hsa-miR-3175 0.8448 0.1257 hsa-miR-548x- 0.87658 0.0164 hsa-miR-30e-5p 0.82168 0.0439 hsa-miR-30a-5p 0.8458 0.2013 3p hsa-miR-574-3p 0.87658 0.0657 hsa-miR-331-5p 0.82218 0.0271 hsa-miR-23a-3p 0.8478 0.3381 hsa-miR-455-3p 0.8791 0.151 hsa-miR-223-3p 0.82409 0.252 hsa-miR-147b 0.8489 0.0448 hsa-miR-409-3p 0.88122 0.0383 hsa-miR-28-3p 0.82816 0.06 hsa-miR-1252 0.8497 0.0297 hsa-miR-520h 0.88512 0.1182 hsa-miR-487b 0.83064 0.0901 hsa-miR-494 0.8534 0.5664 hsa-miR-30e-5p 0.88546 0.1542 hsa-miR-941 0.83681 0.0134 hsa-let-7e-5p 0.855 0.3462 hsa-let-7b-5p 0.88572 0.2839 hsa-miR-598 0.83935 0.1527 hsa-miR-27a-3p 0.8569 0.1123 hsa-miR-570-3p 0.88585 0.2204 hsa-miR-3934 0.83946 0.0357 hsa-miR-519e- 0.8577 0.0654 3p hsa-miR-613 0.88767 0.0886 hsa-miR-1303 0.84322 0.4554 hsa-miR-219-5p 0.8614 0.0692 hsa-miR-361-3p 0.88855 0.0404 hsa-miR-154-5p 0.84332 0.022 hsa-miR-576-5p 0.8647 0.3077 hsa-miR-219-5p 0.88944 0.0864 hsa-miR-3123 0.84833 0.0809 hsa-let-7i-5p 0.8667 0.3005 hsa-miR-5481 0.88987 0.147 hsa-miR-582-5p 0.85037 0.1998 hsa-miR-340-5p 0.8671 0.2222 hsa-miR-548i 0.89029 0.2241 hsa-miR-499a- 0.85063 0.107 hsa-miR-30b-5p 0.8705 0.47 3p hsa-miR-1281 0.89159 0.1645 hsa-miR-647 0.85363 0.0661 hsa-miR-18a-5p 0.8711 0.0366 hsa-miR-320a 0.89169 0.1508 hsa-miR-362-3p 0.85368 0.1384 hsa-miR-125a- 0.8721 0.1376 3p hsa-miR-548t-5p 0.89363 0.054 hsa-miR-1909- 0.85371 0.0876 hsa-miR-329 0.8762 0.152 3p hsa-miR-329 0.89653 0.1554 hsa-miR-4647 0.85411 0.0498 hsa-miR-193b- 0.8786 0.297 3p hsa-miR-27a-3p 0.89721 0.1793 hsa-miR-1197 0.85476 0.104 hsa-miR-548k 0.8798 0.0902 hsa-miR-330-3p 0.89791 0.1081 hsa-miR-568 0.8551 0.1413 hsa-miR-218-5p 0.8801 0.2557 hsa-miR-936 0.89831 0.1364 hsa-miR-378a- 0.85528 0.1533 hsa-miR-1197 0.8835 0.2242 3p?miR-378i hsa-miR-548ai 0.90028 0.2245 hsa-miR-4516 0.8565 0.3469 hsa-miR-199b- 0.8862 0.514 5p hsa-miR-511 0.90062 0.1724 hsa-miR-147b 0.85907 0.0481 hsa-miR-502-3p 0.8885 0.2353 hsa-miR-520d- 0.90099 0.3025 hsa-miR-133b 0.86212 0.0552 hsa-miR-130b- 0.8898 0.0765 5p?miR-518a- 3p hsa-miR-1244 0.9021 0.1306 hsa-miR-132-3p 0.86318 0.1577 hsa-miR-1288 0.8904 0.1939 hsa-miR-28-3p 0.90283 0.2441 hsa-miR-644a 0.86469 0.0453 hsa-miR-324-5p 0.8923 0.2856 hsa-miR-133b 0.90719 0.1516 hsa-miR-576-5p 0.86526 0.2811 hsa-miR-331-3p 0.8926 0.1019 hsa-miR-1294 0.90865 0.131 hsa-miR-331-3p 0.86535 0.0288 hsa-let-7c 0.893 0.4757 hsa-miR-502-3p 0.9112 0.2624 hsa-miR-448 0.87229 0.0892 hsa-miR-885-5p 0.8939 0.1828 hsa-miR-548a- 0.91163 0.2632 hsa-miR-125a- 0.87331 0.1192 hsa-miR-409-3p 0.8949 0.1254 5p 3p hsa-miR-127-3p 0.91175 0.2156 hsa-miR-4284 0.87385 0.2568 hsa-miR-574-3p 0.8955 0.195 hsa-miR-4421 0.91184 0.1852 hsa-miR-483-3p 0.87497 0.1434 hsa-miR-195-5p 0.8973 0.4947 hsa-miR-487b 0.91329 0.3443 hsa-miR-381 0.87604 0.08 hsa-miR-660-5p 0.8974 0.3295 hsa-miR-3161 0.91548 0.2538 hsa-miR-15b-5p 0.87891 0.3149 hsa-miR-148b- 0.8981 0.2877 3p hsa-miR-520b 0.91619 0.175 hsa-miR-508-5p 0.87897 0.192 hsa-miR-154-5p 0.8982 0.1667 hsa-let-7a-5p 0.91625 0.5293 hsa-miR-195-5p 0.88028 0.394 hsa-miR-133a 0.8985 0.5882 hsa-miR-553 0.91766 0.3302 hsa-miR-337-5p 0.88047 0.1197 hsa-miR-338-3p 0.9002 0.2716 hsa-miR-519b- 0.91824 0.2904 hsa-miR-450b- 0.8811 0.1456 hsa-miR-95 0.9004 0.1652 5p?miR-519c- 5p hsa-miR-342-3p 0.91988 0.4973 hsa-miR-194-5p 0.88202 0.102 hsa-miR-185-5p 0.9037 0.136 hsa-miR-548v 0.92183 0.2955 hsa-miR-1281 0.88308 0.1821 hsa-miR-216a 0.9049 0.341 hsa-miR-513a- 0.92256 0.4578 hsa-miR-33a-5p 0.88454 0.0966 hsa-miR-3928 0.9059 0.2575 3p hsa-miR-664-3p 0.92369 0.437 hsa-miR-9-5p 0.88546 0.2947 hsa-miR-627 0.906 0.1383 hsa-miR-376b 0.92459 0.1983 hsa-miR-181b- 0.88642 0.1328 hsa-miR-136-5p 0.9064 0.3979 5p?miR-181d hsa-miR-210 0.92523 0.2923 hsa-miR-362-5p 0.88765 0.1486 hsa-miR-187-3p 0.9072 0.3855 hsa-miR-603 0.92617 0.3078 hsa-miR-566 0.88865 0.0945 hsa-miR-212-3p 0.9079 0.11 hsa-miR-196b- 0.92757 0.3763 hsa-miR-605 0.89644 0.1065 hsa-miR-487b 0.9095 0.4092 5p hsa-miR-4516 0.92986 0.6167 hsa-miR-299-3p 0.89717 0.3452 hsa-miR-3168 0.9132 0.3994 hsa-miR-190a 0.93095 0.3815 hsa-miR-3928 0.89766 0.1901 hsa-miR-4448 0.914 0.4098 hsa-miR-525-3p 0.93423 0.3643 hsa-miR-1208 0.89912 0.1483 hsa-miR-891a 0.914 0.2676 hsa-miR-151a- 0.93664 0.3061 ha-miR-361-3p 0.89914 0.1001 hsa-miR-7-5p 0.9143 0.3712 3p hsa-miR-451a 0.93687 0.7793 hsa-miR-330-3p 0.90075 0.166 hsa-miR-4431 0.9159 0.4413 hsa-miR-337-3p 0.93766 0.2066 hsa-miR-654-5p 0.90227 0.2121 hsa-miR-125b- 0.917 0.6024 5p hsa-miR-2053 0.93773 0.2563 hsa-miR-1234 0.90353 0.4511 hsa-miR-28-3p 0.9173 0.4106 hsa-miR-767-3p 0.93809 0.5095 hsa-miR-2054 0.90621 0.4352 hsa-miR-1299 0.9188 0.4891 hsa-miR-146a- 0.93873 0.553 hsa-miR-212-3p 0.90683 0.0867 hsa-miR-1273e 0.9197 0.6613 5p hsa-miR-154-5p 0.93892 0.328 hsa-miR-503 0.90715 0.2236 hsa-miR-4516 0.9211 0.6372 hsa-miR-1246 0.93942 0.5169 hsa-miR-4454 0.9119 0.5378 hsa-miR-635 0.9254 0.4293 hsa-miR-1268a 0.93999 0.5754 hsa-miR-302e 0.91322 0.198 hsa-miR-130a- 0.9257 0.6682 3p hsa-miR-1179 0.94024 0.4189 hsa-miR-18a-5p 0.91533 0.15 hsa-miR-128 0.9273 0.3585 hsa-miR-502-5p 0.94069 0.4311 hsa-miR-4741 0.91789 0.2047 hsa-miR-30e-5p 0.928 0.462 hsa-miR-579 0.94091 0.4659 hsa-miR-1539 0.92148 0.2789 hsa-miR-1206 0.9294 0.4775 hsa-miR-216b 0.9414 0.3302 hsa-miR-494 0.9244 0.7625 hsa-miR-551a 0.9305 0.2295 hsa-miR-876-3p 0.94278 0.4558 hsa-miR-374b- 0.92559 0.5775 hsa-miR-1287 0.9321 0.2824 5p hsa-miR-720 0.94824 0.7109 hsa-miR-551a 0.92991 0.1986 hsa-miR-503 0.9347 0.4246 hsa-miR-1231 0.94873 0.4796 hsa-miR-10a-5p 0.93342 0.1992 hsa-miR-146b- 0.9353 0.6001 5p hsa-miR-769-3p 0.94997 0.3611 hsa-miR-4488 0.93445 0.6736 hsa-miR-27b-3p 0.9353 0.7453 hsa-miR-604 0.95019 0.5286 hsa-miR-1180 0.93497 0.4574 hsa-miR-542-5p 0.9378 0.6131 hsa-miR-29c-3p 0.95054 0.7542 hsa-miR-766-3p 0.9357 0.3968 hsa-miR-3605- 0.9385 0.463 5p hsa-miR-769-5p 0.95101 0.5758 hsa-miR-548v 0.93764 0.4626 hsa-miR-605 0.9414 0.3969 hsa-miR-605 0.9522 0.4093 hsa-miR-590-5p 0.93952 0.3375 hsa-miR-600 0.9439 0.6542 hsa-miR-4531 0.95225 0.544 hsa-miR-660-5p 0.94003 0.5529 hsa-miR-26b-5p 0.9456 0.7157 hsa-miR-149-5p 0.95254 0.6534 hsa-miR-585 0.9468 0.5064 hsa-miR-3196 0.9483 0.4982 hsa-miR-629-5p 0.95263 0.427 hsa-miR-663a 0.94768 0.6205 hsa-miR-133b 0.9503 0.5282 hsa-miR-762 0.95392 0.4759 hsa-miR-320a 0.9515 0.578 hsa-miR-24-3p 0.9534 0.7878 hsa-miR-1260a 0.95424 0.733 hsa-miR-500a- 0.95526 0.4835 hsa-miR-145-5p 0.9537 0.8626 5p?miR-501-5 hsa-miR-944 0.9554 0.5858 hsa-miR-593-3p 0.95687 0.7196 hsa-miR-548ak 0.9541 0.6052 hsa-miR-548g- 0.95594 0.5799 hsa-let-7b-5p 0.95718 0.731 hsa-miR-222-3p 0.955 0.795 3p ha-miR-891b 0.95622 0.567 hsa-miR-185-5p 0.95726 0.4907 hsa-miR-10a-5p 0.9559 0.4257 hsa-miR-342-5p 0.95759 0.7714 hsa-miR-548x- 0.95727 0.4694 hsa-miR-1238 0.9576 0.606 3p hsa-miR-877-5p 0.95936 0.5789 hsa-miR-146b- 0.95881 0.7263 hsa-miR-1973 0.9599 0.6683 5p hsa-miR-548z 0.96001 0.6945 hsa-miR-885-5p 0.96225 0.6247 hsa-miR-622 0.9605 0.7344 hsa-miR-4461 0.96024 0.4531 hsa-miR-4421 0.9656 0.654 hsa-miR-631 0.9607 0.6559 hsa-miR-3131 0.96062 0.6035 hsa-miR-4448 0.9657 0.7335 hsa-miR-361-5p 0.9661 0.8247 hsa-miR-107 0.96199 0.6981 hsa-miR-1299 0.96591 0.7633 hsa-miR-578 0.9666 0.613 hsa-miR-422a 0.96403 0.517 hsa-miR-142-3p 0.96685 0.8702 hsa-miR-99b-5p 0.9694 0.7629 hsa-miR-1224- 0.96518 0.6597 hsa-miR-190a 0.96758 0.7205 hsa-miR-4286 0.9696 0.9182 5p hsa-miR-1200 0.96529 0.6354 hsa-miR-603 0.96817 0.7022 hsa-miR-2110 0.97 0.726 hsa-miR-514b- 0.96682 0.5939 hsa-miR-1827 0.96837 0.6848 hsa-miR-585 0.972 0.7443 5p hsa-miR-1197 0.96745 0.6949 hsa-miR-146a- 0.96956 0.7971 hsa-miR-188-5p 0.9721 0.6888 5p hsa-miR-331-3p 0.96949 0.5881 hsa-miR-422a 0.97541 0.6963 hsa-miR-3123 0.9729 0.7805 hsa-miR-922 0.96962 0.7249 hsa-miR-1183 0.97607 0.84 hsa-miR-15a-5p 0.9742 0.8672 hsa-miR-503 0.97056 0.6713 hsa-miR-2053 0.9774 0.7194 hsa-miR-758 0.9759 0.7889 hsa-miR-641 0.97173 0.6183 hsa-miR-614 0.97769 0.8319 hsa-miR-491-5p 0.9767 0.7886 hsa-miR-585 0.97412 0.7183 hsa-miR-1287 0.97848 0.7228 hsa-miR-1286 0.9795 0.778 hsa-miR-10b-5p 0.97556 0.8255 hsa-miR-376a- 0.98049 0.8793 hsa-miR-3182 0.9801 0.8843 3p hsa-miR-10a-5p 0.97653 0.6146 hsa-miR-148b- 0.9821 0.8487 hsa-miR-1205 0.9808 0.8358 3p hsa-miR-302d- 0.97696 0.6623 hsa-miR-216a 0.98215 0.8548 hsa-miR-484 0.9833 0.7766 3p hsa-miR-541-3p 0.97753 0.8314 hsa-miR-15a-5p 0.98227 0.9032 hsa-miR-98 0.9841 0.9139 hsa-miR-140-3p 0.97853 0.8558 hsa-miR-10b-5p 0.98273 0.8907 hsa-miR-548an 0.9876 0.8702 hsa-miR-548d- 0.98011 0.8023 hsa-miR-519e- 0.98275 0.8217 hsa-miR-644a 0.9891 0.8846 5p 3p hsa-miR-195-5p 0.98098 0.8843 hsa-miR-769-3p 0.98299 0.7862 hsa-miR-1281 0.9905 0.9221 hsa-miR-135a- 0.98215 0.9142 hsa-miR-4461 0.98448 0.7975 hsa-miR-550a- 0.9906 0.9103 5p 5p hsa-miR-1323 0.98516 0.8577 hsa-miR-548ak 0.98669 0.8754 hsa-miR-181c- 0.9922 0.9423 5p hsa-miR-200a- 0.9872 0.9468 hsa-miR-340-5p 0.98783 0.9107 hsa-miR-4532 0.9927 0.9613 3p ha-miR-1305 0.98728 0.8947 hsa-miR-3131 0.98788 0.8889 hsa-miR-221-3p 0.9938 0.977 hsa-miR-890 0.98839 0.8723 hsa-miR-4458 0.99005 0.938 hsa-miR-450a- 0.9938 0.9491 5p hsa-miR-26a-5p 0.98867 0.9514 hsa-miR-553 0.99174 0.9334 hsa-miR-1273d 0.9955 0.9538 hsa-miR-449a 0.98895 0.9066 hsa-miR-3196 0.99292 0.9232 hsa-miR-320e 0.9963 0.9778 hsa-miR-3928 0.99091 0.8995 hsa-miR-1252 0.99342 0.9236 hsa-miR-365a- 0.9967 0.9803 3p hsa-miR-1913 0.99104 0.9241 hsa-miR-938 0.99533 0.9443 hsa-miR-371a- 0.9967 0.9803 5p hsa-miR-612 0.99148 0.8915 hsa-let-7a-5p 0.9975 0.9873 hsa-miR-3690 0.9968 0.9678 hsa-miR-3147 0.99367 0.9534 hsa-miR-361-5p 1.00123 0.9933 hsa-miR-302b- 0.9995 0.9956 3p hsa-miR-3136- 0.99724 0.9673 hsa-miR-629-5p 1.00218 0.9748 hsa-miR-142-5p 1.0002 0.9981 5p hsa-miR-383 0.99746 0.9707 hsa-miR-107 1.0038 0.9732 hsa-miR-191-5p 1.0025 0.9854 hsa-miR-517c- 0.99763 0.9773 hsa-miR-337-3p 1.00518 0.9279 hsa-miR-330-3p 1.0032 0.9683 3p?miR-519a- hsa-miR-212-3p 0.99888 0.982 hsa-miR-210 1.00523 0.9498 hsa-miR-1193 1.0049 0.9587 hsa-miR-551a 0.99937 0.9899 hsa-miR-144-3p 1.00627 0.9677 hsa-miR-193a- 1.0069 0.9495 3p hsa-miR-301a- 0.99944 0.9949 hsa-miR-1286 1.01378 0.8432 hsa-miR-10b-5p 1.0074 0.9566 3p hsa-miR-576-5p 1.00059 0.996 hsa-miR-877-5p 1.01405 0.8686 hsa-miR-125a- 1.0087 0.9494 5p hsa-miR-125a- 1.00141 0.9852 hsa-miR-600 1.01741 0.887 hsa-miR-99a-5p 1.0092 0.9567 3p hsa-miR-4443 1.00348 0.9786 hsa-miR-548t-5p 1.01855 0.7764 hsa-let-7f-5p 1.0109 0.95 hsa-miR-1290 1.00524 0.9724 hsa-miR-3690 1.01992 0.7911 hsa-miR-422a 1.0118 0.8623 hsa-miR-562 1.00627 0.9219 hsa-miR-382-5p 1.02019 0.7998 hsa-miR-361-3p 1.0119 0.8611 hsa-miR-21-5p 1.00693 0.9603 hsa-miR-3195 1.03104 0.8727 hsa-miR-376c 1.0158 0.8726 hsa-miR-30d-5p 1.00729 0.9464 hsa-miR-3175 1.03184 0.76 hsa-miR-129-2- 1.0161 0.8436 3p hsa-miR-941 1.00742 0.9047 hsa-miR-193a- 1.03188 0.7587 hsa-miR-548v 1.0171 0.8547 3p hsa-miR-15a-5p 1.00825 0.9497 hsa-miR-135b- 1.03315 0.7435 hsa-miR-151a- 1.019 0.8623 5p 5p hsa-miR-192-5p 1.0087 0.8649 hsa-miR-425-5p 1.03877 0.6823 hsa-miR-181b- 1.0229 0.788 5p?miR-181d hsa-miR-892b 1.01175 0.9175 hsa-miR-151a- 1.04061 0.5803 hsa-miR-4461 1.0252 0.7002 3p hsa-miR-147b 1.012 0.858 hsa-miR-1908 1.04193 0.7106 hsa-miR-3131 1.0284 0.7627 hsa-miR-1257 1.01212 0.8746 hsa-miR-2110 1.04254 0.611 hsa-miR-146a- 1.0328 0.8001 5p hsa-miR-3180 1.01242 0.8766 hsa-miR-484 1.04274 0.4547 hsa-miR-769-3p 1.0348 0.6112 hsa-miR-596 1.01273 0.9014 hsa-miR-30b-5p 1.04349 0.8134 hsa-miR-3676- 1.0366 0.7464 3p hsa-miR-582-5p 1.01275 0.9091 hsa-miR-1226- 1.04564 0.6148 hsa-miR-190a 1.0393 0.693 3p hsa-miR-564 1.0135 0.8579 hsa-miR-450b- 1.04638 0.6959 hsa-miR-483-3p 1.0393 0.6879 3p hsa-miR-498 1.01664 0.863 hsa-miR-485-3p 1.04692 0.6253 hsa-miR-126-3p 1.0405 0.8198 hsa-miR-139-3p 1.0177 0.7956 hsa-miR-203 1.04832 0.6632 hsa-miR-299-3p 1.0409 0.7414 hsa-miR-764 1.01891 0.8182 hsa-miR-550a- 1.04838 0.5521 hsa-miR-337-5p 1.0412 0.6385 5p hsa-miR-573 1.01961 0.8305 hsa-miR-514b- 1.04867 0.5067 hsa-miR-2053 1.0423 0.5401 5p hsa-miR-516a- 1.01963 0.7684 hsa-miR-491-5p 1.04893 0.5647 hsa-miR-378a- 1.0427 0.7163 3p 3p?miR-3781 hsa-miR-410 1.01972 0.7527 hsa-miR-621 1.04955 0.4936 hsa-miR-107 1.0435 0.7225 hsa-miR-140-5p 1.02101 0.8498 hsa-miR-130b- 1.05035 0.4229 hsa-miR-603 1.0453 0.6216 3p hsa-miR-330-5p 1.02157 0.7477 hsa-miR-3168 1.05144 0.6205 hsa-miR-381 1.0454 0.5748 hsa-miR-577 1.02282 0.7785 hsa-miR-1288 1.05462 0.525 hsa-miR-629-5p 1.052 0.4887 hsa-miR-3690 1.02317 0.7281 hsa-miR-520b 1.05982 0.4228 hsa-miR-581 1.0548 0.5738 hsa-miR-193a- 1.02481 0.7863 hsa-miR-532-5p 1.06335 0.764 hsa-miR-877-5p 1.057 0.5365 3p hsa-miR-146b- 1.02518 0.8151 hsa-miR-302a- 1.06923 0.4786 hsa-miR-139-3p 1.0571 0.4952 5p 3p hsa-miR-524-3p 1.02594 0.7721 hsa-miR-383 1.06984 0.3905 hsa-miR-4421 1.059 0.4902 hsa-miR-374a- 1.02648 0.8398 hsa-miR-4455 1.07281 0.3845 hsa-miR-196a- 1.0616 0.4664 5p 5p hsa-miR-628-3p 1.02729 0.714 hsa-miR-196b- 1.07565 0.4471 hsa-miR-106b- 1.0617 0.589 5p 5p hsa-miR-638 1.02794 0.7089 hsa-miR-139-3p 1.0758 0.3417 hsa-miR-331-5p 1.0657 0.4888 hsa-miR-626 1.02835 0.7848 hsa-miR-7-5p 1.07688 0.4321 hsa-miR-455-5p 1.0658 0.4954 hsa-miR-1909- 1.02898 0.7237 hsa-miR-622 1.07817 0.5021 hsa-miR-197-3p 1.0665 0.4606 3p hsa-miR-1245b- 1.02975 0.7085 hsa-miR-1205 1.07905 0.3892 hsa-miR-601 1.0667 0.692 5p hsa-miR-569 1.03288 0.6721 hsa-miR-515-5p 1.07934 0.4344 hsa-miR-670 1.0668 0.3681 hsa-miR-548ak 1.03411 0.6576 hsa-miR-892b 1.07993 0.5468 hsa-miR-320a 1.0671 0.4941 hsa-miR-1286 1.03498 0.5748 hsa-miR-1294 1.08157 0.2713 hsa-miR-892b 1.0674 0.63 hsa-miR-134 1.03615 0.6441 hsa-miR-548q 1.08185 0.4539 hsa-miR-569 1.0698 0.4628 hsa-miR-361-5p 1.03639 0.7832 hsa-miR-128 1.08235 0.3071 hsa-miR-519d 1.0709 0.4525 hsa-miR-23c 1.03653 0.7424 hsa-miR-5481 1.0843 0.3701 hsa-miR-337-3p 1.072 0.2546 hsa-miR-670 1.03753 0.5374 hsa-miR-548k 1.08475 0.2493 hsa-miR-383 1.0726 0.4012 hsa-miR-519d 1.03845 0.6192 hsa-miR-151a- 1.08674 0.4176 hsa-miR-4647 1.0729 0.4024 5p hsa-miR-367-3p 1.03879 0.5742 hsa-miR-188-5p 1.08676 0.2146 hsa-miR-367-3p 1.0791 0.3501 hsa-miR-548ad 1.03888 0.5374 hsa-miR-1224- 1.08747 0.3582 hsa-miR-510 1.0792 0.4039 5p hsa-miR-1202 1.03909 0.6248 hsa-miR-3182 1.09454 0.4881 hsa-miR-30c-5p 1.0799 0.6524 hsa-miR-486-3p 1.04377 0.6742 hsa-miR-95 1.0959 0.198 hsa-let-7b-5p 1.0807 0.5663 hsa-miR-208a 1.04663 0.6111 hsa-miR-890 1.09663 0.2639 hsa-miR-553 1.0807 0.4624 hsa-miR-3196 1.04706 0.4816 hsa-miR-3676- 1.09698 0.3779 hsa-miR-548am- 1.0814 0.4381 3p 3p hsa-miR-660-5p 1.04747 0.6149 hsa-miR-604 1.09738 0.312 hsa-miR-34c-3p 1.0838 0.4174 hsa-miR-2276 1.04751 0.522 hsa-miR-320e 1.09932 0.4561 hsa-miR-514b- 1.0847 0.2865 5p hsa-miR-2682- 1.04912 0.534 hsa-miR-2117 1.09951 0.2509 hsa-miR-210 1.0865 0.3483 5p hsa-miR-432-5p 1.0494 0.5044 hsa-miR-511 1.10043 0.2681 hsa-miR-96-5p 1.0866 0.4574 hsa-miR-1287 1.04981 0.3723 hsa-miR-627 1.10058 0.1269 hsa-miR-663b 1.0884 0.5685 hsa-miR-18a-5p 1.05079 0.3594 hsa-miR-569 1.10495 0.2506 hsa-let-7a-5p 1.0887 0.6102 hsa-miR-196a- 1.05109 0.4665 hsa-miR-670 1.1068 0.1364 hsa-miR-4488 1.0908 0.6111 5p hsa-miR-518b 1.05125 0.5167 hsa-miR-411-5p 1.10829 0.1434 hsa-miR-548x- 1.092 0.1723 3p hsa-miR-1299 1.05132 0.6237 hsa-miR-578 1.1098 0.1038 hsa-miR-93-5p 1.0956 0.4768 hsa-miR-495 1.05238 0.4235 hsa-miR-1260b 1.10989 0.3609 hsa-miR-199a- 1.0983 0.5314 5p hsa-miR-16-5p 1.05457 0.7057 hsa-miR-449a 1.11082 0.3282 hsa-miR-4741 1.107 0.1573 hsa-miR-1178 1.05511 0.6021 hsa-miR-376b 1.11204 0.1244 hsa-miR-192-5p 1.1087 0.0955 hsa-miR-4448 1.0566 0.5445 hsa-miR-519d 1.11209 0.2184 hsa-miR-890 1.1095 0.2362 hsa-miR-3676- 1.05827 0.5413 hsa-miR-196a- 1.11584 0.1593 hsa-miR-374b- 1.1097 0.4804 3p 5p 5p hsa-miR-550a- 1.05837 0.4205 hsa-miR-3161 1.11694 0.2067 hsa-miR-151a- 1.111 0.1718 5p 3p hsa-miR-185-5p 1.05923 0.3065 hsa-miR-192-5p 1.11837 0.0561 hsa-miR-638 1.1145 0.2241 hsa-miR-484 1.06042 0.2383 hsa-miR-367-3p 1.12096 0.1394 hsa-miR-142-3p 1.1159 0.617 hsa-miR-576-3p 1.06339 0.6063 hsa-miR-502-5p 1.12695 0.1759 hsa-miR- 1.1185 0.2165 526a?miR-520c- 5p? hsa-miR-194-5p 1.06388 0.3577 hsa-miR-891a 1.12738 0.1188 hsa-miR-1202 1.1207 0.2286 hsa-miR-25-3p 1.06439 0.3626 hsa-miR-548i 1.13004 0.2572 hsa-miR-297 1.121 0.1325 hsa-miR-499a- 1.06446 0.4772 hsa-miR-496 1.13055 0.1337 hsa-miR-449a 1.1232 0.3087 3p hsa-miR-656 1.0651 0.3901 hsa-miR-572 1.13185 0.1951 hsa-miR-100-5p 1.1236 0.4917 hsa-miR-587 1.06598 0.299 hsa-miR-641 1.1324 0.0601 hsa-miR-92a-3p 1.1247 0.28 hsa-miR-151a- 1.06647 0.4782 hsa-miR-542-3p 1.13491 0.0822 hsa-miR-1183 1.1266 0.3514 5p hsa-miR-34c-3p 1.06774 0.4283 hsa-miR-30d-5p 1.13544 0.301 hsa-miR-1224- 1.1267 0.2197 5p hsa-miR-412 1.07032 0.3075 hsa-miR-21-5p 1.13566 0.4183 hsa-miR-30d-5p 1.1272 0.3578 hsa-miR-197-3p 1.07078 0.3479 hsa-miR-197-3p 1.14199 0.1098 hsa-miR-21-5p 1.1278 0.4706 hsa-miR-544a 1.07111 0.2608 hsa-miR-548g- 1.14204 0.1052 hsa-miR-1275 1.1287 0.1227 3p hsa-miR-491-5p 1.07395 0.3326 hsa-miR-541-3p 1.14281 0.2713 hsa-miR-412 1.1317 0.124 hsa-miR-2110 1.07478 0.3216 hsa-miR-638 1.14562 0.1075 hsa-miR-1255b- 1.1388 0.175 5p hsa-miR-335-5p 1.0751 0.3498 hsa-miR-758 1.14772 0.1127 hsa-miR-548t-5p 1.1398 0.0613 hsa-miR-647 1.07538 0.3343 hsa-miR-142-5p 1.149 0.1466 hsa-miR-500a- 1.1415 0.0603 5p?miR-501-5 hsa-miR-384 1.07602 0.4199 hsa-miR-597 1.15015 0.0643 hsa-miR-134 1.1457 0.1441 hsa-miR-885-5p 1.07641 0.2924 hsa-miR-1238 1.15053 0.0802 hsa-miR-587 1.1513 0.0593 hsa-miR-600 1.07793 0.486 hsa-miR-31-5p 1.15316 0.0779 hsa-miR-604 1.1549 0.1422 hsa-miR-362-5p 1.07801 0.3012 hsa-miR-3185 1.15415 0.0901 hsa-miR-520b 1.1568 0.0621 hsa-miR-665 1.08141 0.3907 hsa-miR-635 1.1561 0.1199 hsa-miR-1257 1.1574 0.1152 hsa-miR-1275 1.08173 0.2273 hsa-miR-936 1.15707 0.0744 hsa-miR-196b- 1.1596 0.1489 5p hsa-miR-132-3p 1.08238 0.3874 hsa-miR-34c-3p 1.15727 0.1216 hsa-miR-641 1.1653 0.0302 hsa-miR-200b- 1.08312 0.7339 hsa-miR-1200 1.16154 0.0796 hsa-miR-335-5p 1.1672 0.0993 3p hsa-miR-494 1.08321 0.7285 hsa-miR-762 1.16285 0.0474 hsa-miR-541-3p 1.1691 0.2259 hsa-miR-654-5p 1.08393 0.2684 hsa-miR-1273e 1.16307 0.4026 hsa-miR-524-3p 1.1692 0.1446 hsa-miR-216a 1.08537 0.349 hsa-miR-129-2- 1.164 0.0503 hsa-miR-1180 1.1714 0.1032 3p hsa-miR-516a- 1.0857 0.5371 hsa-miR-1202 1.1645 0.0899 hsa-miR-382-5p 1.1715 0.063 5p hsa-miR-566 1.08683 0.1804 hsa-miR-767-3p 1.16771 0.1599 hsa-miR-3151 1.1766 0.2653 hsa-miR-1234 1.08802 0.4787 hsa-miR-497-5p 1.17009 0.2799 hsa-miR-504 1.1768 0.1087 hsa-miR- 1.08817 0.2627 hsa-miR-664-3p 1.17017 0.176 hsa-miR-515-3p 1.1836 0.0414 526a?miR-520c- 5p? hsa-miR-1303 1.08895 0.6728 hsa-miR-1257 1.17139 0.0714 hsa-miR-516a- 1.1893 0.0324 3p hsa-miR-761 1.09222 0.4538 hsa-miR-548d- 1.17155 0.0852 hsa-miR-1294 1.1903 0.024 5p hsa-miR-548ag 1.09315 0.3109 hsa-miR-155-5p 1.17583 0.0651 hsa-miR-548g- 1.1947 0.0425 3p hsa-miR-301b 1.09334 0.3664 hsa-miR-191-5p 1.18001 0.2107 hsa-miR-4454 1.1953 0.2636 hsa-miR-448 1.09335 0.2066 hsa-miR-563 1.18507 0.1538 hsa-miR-548d- 1.1953 0.0682 5p hsa-miR-423-3p 1.0935 0.0886 hsa-miR-548n 1.18543 0.0447 hsa-miR-502-5p 1.198 0.0562 hsa-miR-148b- 1.09351 0.2887 hsa-miR-1973 1.18692 0.0609 hsa-miR-22-3p 1.1981 0.2657 3p hsa-miR-924 1.09646 0.2791 hsa-miR-134 1.18709 0.0525 hsa-miR-376b 1.2027 0.0136 hsa-miR-568 1.0981 0.3176 hsa-miR-548am- 1.19409 0.0657 hsa-miR-1200 1.2033 0.0423 3p hsa-miR-3151 1.09854 0.4385 hsa-miR-514a- 1.19528 0.0294 hsa-miR-486-3p 1.2044 0.1323 3p hsa-miR-3934 1.09913 0.1938 hsa-miR-612 1.19691 0.014 hsa-miR-612 1.2072 0.0152 hsa-miR-1539 1.09995 0.1558 hsa-miR-510 1.19719 0.0399 hsa-miR-498 1.2074 0.1049 hsa-miR-1205 1.10016 0.224 hsa-miR-524-3p 1.19951 0.0731 hsa-miR-378b 1.2079 0.0263 hsa-miR-323a- 1.10052 0.1961 hsa-miR-1273d 1.19973 0.0161 hsa-miR-621 1.215 0.0117 3p hsa-miR-518c- 1.10129 0.3015 hsa-miR-449c- 1.19997 0.0133 hsa-miR-5481 1.2185 0.0427 3p 5p hsa-miR-320e 1.10345 0.3818 hsa-miR-613 1.20146 0.0218 hsa-miR-762 1.219 0.0152 hsa-miR-548am- 1.10426 0.2401 hsa-miR-1193 1.20585 0.0402 hsa-miR-630 1.2198 0.3633 3p hsa-miR-1277- 1.10537 0.2115 hsa-miR-944 1.20636 0.0514 hsa-miR-144-3p 1.2201 0.2275 3p hsa-miR-548a- 1.10666 0.1136 hsa-miR-1322 1.208 0.2103 hsa-miR-3161 1.2201 0.035 3p hsa-miR-508-3p 1.1088 0.2365 hsa-miR-3605- 1.20972 0.0225 hsa-miR-511 1.2219 0.0318 5p hsa-miR-510 1.10934 0.1753 hsa-miR-548an 1.21068 0.0102 hsa-miR-421 1.2246 0.1195 hsa-miR-15b-5p 1.1094 0.3606 hsa-miR-412 1.21125 0.0131 hsa-miR-924 1.2268 0.0483 hsa-miR-454-3p 1.11064 0.2589 hsa-miR-516a- 1.21267 0.0123 hsa-miR-2054 1.233 0.1213 3p hsa-miR-1255b- 1.11373 0.1774 hsa-miR-548d- 1.21463 0.1382 hsa-miR-301b 1.2334 0.0801 5p 3p hsa-miR-3182 1.11674 0.3393 hsa-miR- 1.2171 0.0238 hsa-miR-767-3p 1.2448 0.0635 526a?miR-520c- 5p? hsa-miR-188-5p 1.11797 0.0627 hsa-miR-1275 1.22092 0.0083 hsa-miR-371a- 1.2516 0.0073 3p hsa-miR-297 1.12112 0.0722 hsa-miR-371a- 1.22316 0.1173 hsa-miR-485-3p 1.2531 0.0271 5p hsa-miR-622 1.12253 0.2463 hsa-miR-548ah- 1.22483 0.0731 hsa-miR-302a- 1.2535 0.0276 5p 3p hsa-miR-302e 1.12332 0.0648 hsa-miR-4431 1.22707 0.0606 hsa-miR-596 1.2572 0.0661 hsa-miR-19a-3p 1.12386 0.2563 hsa-miR-587 1.22728 0.0045 hsa-miR-508-3p 1.258 0.031 hsa-miR-766-3p 1.12453 0.0944 hsa-miR-498 1.22748 0.0623 hsa-miR-183-5p 1.2592 0.0259 hsa-miR-92a-3p 1.12681 0.1893 hsa-miR-335-5p 1.25483 0.0117 hsa-miR-764 1.2607 0.021 hsa-miR-508-5p 1.13265 0.1552 hsa-miR-302b- 1.25595 0.0174 hsa-miR-135b- 1.2626 0.0312 3p 5p hsa-miR-423-5p 1.13314 0.069 hsa-miR-297 1.25673 0.0021 hsa-miR-944 1.2627 0.0234 hsa-miR-598 1.13823 0.2308 hsa-miR-486-3p 1.25706 0.0511 hsa-miR-548ag 1.2653 0.0286 hsa-miR-363-3p 1.13885 0.2874 hsa-miR-581 1.25919 0.0123 hsa-miR-223-3p 1.2656 0.1899 hsa-miR-340-5p 1.13924 0.1814 hsa-miR-1244 1.2611 0.0035 hsa-miR-664-3p 1.2668 0.0573 hsa-miR-129-2- 1.14559 0.0479 hsa-miR-149-5p 1.26297 0.0606 hsa-miR-302f 1.2686 0.0025 3p hsa-miR-519e- 1.14585 0.0505 hsa-miR-92a-3p 1.26733 0.0235 hsa-miR-548i 1.2693 0.0403 3p hsa-miR-1208 1.14691 0.0374 hsa-miR-1246 1.26786 0.0329 hsa-miR-410 1.2701 0.0022 hsa-miR-578 1.14814 0.0164 hsa-miR-1255b- 1.26827 0.0102 hsa-miR-575 1.2703 0.2163 5p hsa-miR-142-5p 1.14872 0.1026 hsa-miR-922 1.26837 0.0195 hsa-miR-544a 1.2712 0.0017 hsa-miR-3168 1.15141 0.1199 hsa-miR-1264 1.27188 0.0104 hsa-miR-106a- 1.2719 0.1073 5p?miR-17-5p hsa-miR-424-5p 1.1535 0.2223 hsa-miR-631 1.27273 0.0062 hsa-miR-376a- 1.2746 0.0827 3p hsa-miR-504 1.15386 0.0913 hsa-miR-596 1.27319 0.0404 hsa-miR-936 1.288 0.0045 hsa-miR-658 1.15814 0.0869 hsa-miR-548aa 1.27905 0.1386 hsa-miR-1178 1.3006 0.037 hsa-miR-371a- 1.16525 0.0265 hsa-miR-764 1.28458 0.0086 hsa-miR-1915- 1.3012 0.1537 3p 3p hsa-miR-450b- 1.16625 0.0478 hsa-miR-3151 1.29255 0.0649 hsa-miR-922 1.3081 0.0133 5p hsa-miR-128 1.1672 0.0271 hsa-miR-616-3p 1.2934 0.0114 hsa-miR-1260b 1.3145 0.027 hsa-miR-20a- 1.16878 0.2296 hsa-miR-410 1.29514 0.0005 hsa-miR-25-3p 1.3189 0.0013 5p?miR-20b-5p hsa-miR-1252 1.16907 0.013 hsa-miR-29c-3p 1.29989 0.1558 hsa-miR-149-5p 1.3259 0.0336 hsa-miR-302f 1.16997 0.015 hsa-miR-1228- 1.30829 0.0011 hsa-miR-411-5p 1.3282 0.0003 3p hsa-miR-421 1.17012 0.1469 hsa-miR-216b 1.31174 0.0003 hsa-miR-542-3p 1.3286 0.0005 hsa-miR-758 1.17605 0.0367 hsa-miR-302d- 1.31527 <.0001 hsa-miR-3136- 1.3334 0.0008 3p 5p hsa-miR-191-5p 1.17701 0.1645 hsa-miR-935 1.31633 0.0124 hsa-miR-548q 1.3404 0.0108 ha-miR-7-5p 1.17781 0.0535 hsa-miR-942 1.31869 0.0027 hsa-miR-3147 1.3417 0.0278 hsa-miR-130b- 1.18037 0.0033 hsa-miR-579 1.31883 0.0048 hsa-miR-31-5p 1.3436 0.0009 3p hsa-miR-429 1.18081 0.3073 hsa-miR-1260a 1.32174 0.0766 hsa-miR-302d- 1.3463 <.0001 3p hsa-miR-802 1.18407 0.0662 hsa-miR-3136- 1.32974 0.0005 hsa-miR-1246 1.3496 0.0119 5p hsa-miR-1288 1.18449 0.0255 hsa-miR-3147 1.33318 0.0226 hsa-miR-613 1.3535 0.0006 hsa-miR-614 1.18719 0.0727 hsa-miR-924 1.34512 0.003 hsa-miR-2117 1.3555 0.001 hsa-miR-33a-5p 1.1875 0.0099 hsa-miR-548y 1.34667 0.0492 hsa-miR-572 1.3599 0.0035 hsa-miR-378b 1.18839 0.0154 hsa-miR-301b 1.34854 0.0094 hsa-miR-496 1.3613 0.0007 hsa-miR-548aj- 1.19351 0.0458 hsa-miR-4286 1.35165 0.2898 hsa-miR-29c-3p 1.3675 0.1115 3p hsa-miR-615-5p 1.19365 0.1238 hsa-miR-504 1.3579 0.002 hsa-miR-19b-3p 1.3688 0.0718 hsa-miR-581 1.19377 0.0285 hsa-miR-570-3p 1.35791 0.0078 hsa-miR-562 1.3735 0.0001 hsa-miR-590-5p 1.19793 0.0026 hsa-miR-1268b 1.3582 0.002 hsa-miR-802 1.3784 0.0045 hsa-miR-30b-5p 1.1987 0.2592 hsa-miR-544a 1.36155 <.0001 hsa-miR-1260a 1.3851 0.0522 hsa-miR-1193 1.19995 0.0246 hsa-miR-1178 1.37223 0.0085 hsa-miR-216b 1.3934 <.0001 hsa-miR-1238 1.20141 0.011 hsa-miR-489 1.38103 0.0002 hsa-miR-1244 1.398 0.0001 hsa-miR-1273d 1.20516 0.0058 hsa-miR-562 1.38213 <.0001 hsa-miR-579 1.4017 0.0013 hsa-miR-19b-3p 1.21303 0.1808 hsa-miR-548ag 1.38318 0.0018 hsa-miR-1322 1.412 0.0338 hsa-miR-627 1.21475 0.0008 hsa-miR-18b-5p 1.38553 0.0077 hsa-miR-573 1.4132 0.0024 hsa-miR-663a 1.21558 0.0461 hsa-miR-663b 1.38979 0.0218 hsa-miR-577 1.4145 0.0007 hsa-miR-95 1.21715 0.0027 hsa-miR-1206 1.39039 0.0013 hsa-miR-514a- 1.4162 0.0001 3p hsa-miR-517a- 1.21862 0.0377 hsa-miR-508-3p 1.39488 0.0013 hsa-miR-892a 1.4259 0.0005 3p hsa-miR-3175 1.22147 0.0313 hsa-miR-25-3p 1.40385 <.0001 hsa-miR-593-3p 1.4283 0.0083 hsa-miR-892a 1.2248 0.0141 hsa-miR-182-5p 1.40985 0.0087 hsa-miR-181a- 1.4317 0.0242 5p hsa-miR-548an 1.22589 0.0023 hsa-miR-548ab 1.4142 0.0412 hsa-miR-576-3p 1.4504 0.0118 hsa-miR-371a- 1.22724 0.0731 hsa-miR-106b- 1.42311 0.0013 hsa-miR-363-3p 1.4607 0.0118 5p 5p hsa-miR-548k 1.23291 0.0014 hsa-miR-4531 1.42635 0.0003 hsa-miR-155-5p 1.4637 0.0001 hsa-miR-891a 1.23345 0.0029 hsa-miR-421 1.43292 0.0044 hsa-miR-429 1.4637 0.0543 hsa-miR-1973 1.23646 0.0099 hsa-miR-378b 1.43551 <.0001 hsa-miR-1245b- 1.4667 0.0002 5p hsa-miR-362-3p 1.24436 0.0227 hsa-miR-520h 1.43753 0.0001 hsa-miR-3195 1.469 0.0621 hsa-miR-635 1.24932 0.0084 hsa-miR-573 1.44089 0.0008 hsa-miR-3185 1.4797 <.0004 hsa-miR-3184- 1.25619 0.006 hsa-miR-577 1.44676 0.0002 hsa-miR-32-5p 1.4894 0.0037 5p hsa-miR-302b- 1.25664 0.0075 hsa-miR-520d- 1.45297 0.0018 hsa-miR-517c- 1.4897 0.0002 3p 5p?miR-518a- 3p?miR-519a- hsa-miR-106a- 1.25898 0.0654 hsa-miR-548ai 1.45619 0.0003 hsa-miR-4531 1.4979 0.0001 5p?miR-17-5p hsa-miR-1827 1.25962 0.0017 hsa-miR-1279 1.45798 <.0001 hsa-miR-616-3p 1.5026 0.0003 hsa-miR-370 1.25977 0.0467 hsa-miR-371a- 1.45845 <.0001 hsa-miR-548d- 1.5065 0.0043 3p 3p hsa-miR-1273e 1.26465 0.1444 hsa-miR-720 1.48248 0.0181 hsa-miR-942 1.5277 <.0001 hsa-miR-203 1.26731 0.0163 hsa-miR-302f 1.48419 <.0001 hsa-miR-1323 1.5307 <.0001 hsa-miR-1915- 1.27027 0.1207 hsa-miR-517c- 1.48621 0.0001 hsa-miR-548ah- 1.531 0.0007 3p 3p?miR-519a- 5p hsa-miR-580 1.27429 0.0058 hsa-miR-1323 1.50795 <.0001 hsa-miR-570-3p 1.5329 0.0006 hsa-ma-1226- 1.27535 0.003 hsa-miR-1245b- 1.51034 <.0001 hsa-miR-497-5p 1.5345 0.0071 3p 5p hsa-miR-9-5p 1.27535 0.0205 hsa-miR-574-5p 1.51405 0.0051 hsa-miR-1228- 1.5372 <.0001 3p hsa-miR-663b 1.27693 0.0524 hsa-miR-513a- 1.52259 0.0011 hsa-miR-548n 1.5422 <.0001 3p hsa-miR-938 1.27983 0.0001 hsa-miR-1276 1.53513 0.031 hsa-miR-548y 1.5616 0.0064 hsa-miR-325 1.28039 0.0181 hsa-miR-550b- 1.54097 <.0001 hsa-miR-720 1.5634 0.0118 3p hsa-miR-219-1- 1.28152 0.0276 hsa-miR-576-3p 1.54229 0.0022 hsa-miR-19a-3p 1.5669 0.0006 3p hsa-miR-3605- 1.28898 0.0009 hsa-miR-888-5p 1.55099 0.0031 hsa-miR-489 1.5792 <.0001 5p hsa-miR-575 1.29601 0.1098 hsa-miR-548a- 1.5683 <.0001 hsa-miR-1913 1.5939 0.0001 5p hsa-miR-654-3p 1.29972 0.0057 hsa-miR-93-5p 1.5733 0.0004 hsa-miR-20a- 1.6015 0.0035 5p?miR-20b-5p hsa-miR-630 1.30837 0.1428 hsa-miR-1913 1.57965 <.0001 hsa-miR-1268b 1.6019 <.0001 hsa-miR-4455 1.31987 0.0003 hsa-miR-1179 1.58098 <.0001 hsa-miR-597 1.6125 <.0001 hsa-miR-659-3p 1.32046 0.001 hsa-miR-601 1.59139 0.0037 hsa-miR-520d- 1.6126 0.0002 5p?miR-518a- hsa-miR-631 1.32484 0.0004 hsa-miR-630 1.59598 0.0262 hsa-miR-375 1.6127 0.0491 hsa-miR-425-5p 1.32618 0.0011 hsa-miR-106a- 1.60127 0.0013 hsa-miR-548ai 1.6175 <.0001 5p?miR-17-5p hsa-miR-450b- 1.33027 0.0073 hsa-miR-200a- 1.61908 0.0311 hsa-miR-520h 1.6241 <.0001 3p 3p hsa-miR-4431 1.33974 0.0032 hsa-miR-802 1.63217 <.0001 hsa-miR-200a- 1.6401 0.0368 3p hsa-miR-106b- 1.34038 0.0025 hsa-miR-2116- 1.63751 0.001 hsa-miR-513a- 1.6504 0.0003 5p 5p 3p hsa-miR-1908 1.37633 0.0019 hsa-miR-575 1.64634 0.00578 hsa-miR-1264 1.6585 <.0001 hsa-miR-4286 1.394 0.1887 hsa-miR-1915- 1.65293 0.005 hsa-miR-1179 1.6815 <.0001 3p hsa-miR-515-3p 1.40777 <.0001 hsa-miR-19b-3p 1.66034 0.0027 hsa-miR-935 1.6999 <.0001 hsa-miR-606 1.42222 0.0011 ha-miR-363-3p 1.66351 0.0005 hsa-miR-18b-5p 1.7129 <.0001 hsa-miR-4458 1.4324 0.0026 hsa-miR-515-3p 1.66629 <.0001 hsa-miR-548a- 1.7203 <.0001 5p hsa-miR-93-5p 1.43606 0.0013 hsa-miR-137 1.72395 0.1104 hsa-miR-548ab 1.7583 0.0023 hsa-miR-449c- 1.44412 <.0001 hsa-miR-429 1.72835 0.0041 hsa-miR-550b- 1.7702 <.0001 5p 3p hsa-miR-548p 1.45236 0.0005 hsa-miR-892a 1.74648 <.0001 hsa-miR-888-5p 1.7787 0.0003 hsa-miR-183-5p 1.453 <.0001 hsa-miR-19a-3p 1.76095 <.0001 hsa-miR-1279 1.8332 <.0001 hsa-miR-1185- 1.45658 0.0001 hsa-miR-549 1.77031 0.0141 hsa-miR-135a- 1.8694 0.0029 5p 5p hsa-miR-548al 1.47105 <.0001 hsa-miR-1268a 1.79717 <.0001 hsa-miR-548aa 1.8924 0.0006 hsa-miR-563 1.49178 0.0003 hsa-miR-96-5p 1.79891 <.0001 hsa-miR-574-5p 1.9046 <.0001 hsa-miR-601 1.49193 0.0047 hsa-miR-183-5p 1.82967 <.0001 hsa-miR-1268a 1.9119 <.0001 hsa-miR-1206 1.49602 <.0001 hsa-miR-135a- 1.83599 0.0022 hsa-miR-2116- 1.963 <.0001 5p 5p hsa-miR-515-5p 1.49971 <.0001 hsa-miR-378e 1.8429 0.0089 hsa-miR-1290 2.1367 0.0001 hsa-miR-4425 1.55984 0.0006 hsa-miR-20a- 1.87176 <.0001 hsa-miR-1276 2.1448 0.0005 5p?miR-20b-5p hsa-miR-4284 1.56506 <.0001 hsa-miR-1972 1.99892 0.0212 hsa-miR-200b- 2.2761 0.005 3p hsa-miR-32-5p 1.57407 0.0001 hsa-miR-1290 2.14789 <.0001 hsa-miR-148a- 2.2933 0.0007 3p hsa-miR-532-5p 1.57499 0.0149 hsa-miR-1253 2.27081 0.0066 hsa-miR-1305 2.6512 <.0001 hsa-miR-96-5p 1.65561 <.0001 hsa-miR-32-5p 2.34437 <.0001 hsa-miR-205-5p 2.6739 0.0443 hsa-miR-4508 1.68748 <.0001 hsa-miR-200b- 2.46532 0.0013 hsa-miR-1972 2.7586 0.0019 3p hsa-miR-148a- 1.74273 0.0054 hsa-miR-1305 2.61745 <.0001 hsa-miR-141-3p 2.9576 <.0001 3p hsa-miR-141-3p 1.76447 0.0041 hsa-miR-1283 3.45147 0.0114 hsa-miR-200c- 3.0052 0.0002 3p hsa-miR-182-5p 1.91808 <.0001 hsa-miR-375 3.85162 <.0001 hsa-miR-378e 3.5063 <.0001 hsa-miR-200c- 1.99681 0.0038 hsa-miR-148a- 3.99653 <.0001 hsa-miR-549 3.5135 <.0001 3p 3p hsa-miR-137 2.07477 0.0173 hsa-miR-141-3p 5.21869 <.0001 hsa-miR-1253 5.3773 <.0001 hsa-miR-375 2.38831 <.0001 hsa-miR-200c- 6.00079 <.0001 hsa-miR-1283 13.122 <.0001 3p

Tumor samples had 7 miRNAs upregulated and 25 downregulated compared to both epithelium and stroma tissue, whereas epithelium samples had 5 miRNAs upregulated and 3 downregulated compared to tumor and stroma (FIG. 1). FIG. 1 is a Venn diagram showing numbers of commonly and differentially expressed miRNAs in prostate tumor, stroma, and epithelium. miRNAs commonly expressed among all tissue types as well as those significantly differentially expressed 1.5-fold or greater between all tissues types, using the repeated measures ANOVA are shown. miRNAs that were up-regulated (dark grey) and down-regulated (light grey) were identified in specific tissues meaning they were differentially expressed 1.5-fold or greater compared to the other two tissue types. Stroma samples appeared to be the most different when compared to either tumor or epithelium with 27 miRNAs upregulated and 23 downregulated (FIGS. 1 and 2). FIG. 2 gives the names of the miRNAs that were differentially expressed 1.5-fold or greater between all tissues types, using the repeated measures ANOVA. miR-1283 and miR-137 were for the first time identified to be deregulated in prostate tumor tissue compared to epithelium (Table 1).

miRNAs Predictive of PSA Recurrence Post-Prostatectomy: Univariate Analysis.

A clinical database was established for 43 PCa patients who underwent both RP and salvage RT Table 5. Risk factors included 32.5% of patients who had a Gleason score of 8 or above, 25.6% of patients who had seminal vesicle invasion or extraprostatic extension, and 41.9% of patients who had positive margins. Salvage RT was started at a median PSA value of 0.39 ng/ml. 19 patients (44.2%) experienced BF after salvage RT at a median time of 47.7 months (range 18.4-138.0 months). The median follow up times after RP and after salvage RT were 6.9 and 3.7 years, respectively.

TABLE 5 Clinical characteristics of 43 prostate cancer patients treated with salvage radiation therapy post-prostatectomy PCa patients (n = 43) Age at RP (years) 65 Median (min-max) (45-73) Follow-up post-RP (years) 6.9 Median (min-max) (4.0-139) Gleason score  6 8 (18.6%)  7 21 (48.8%)  8 8 (18.6%)  9 5 (11.6%) 10 1 (2.3%) Pathological Tumor Stage T2 32 (74.4%) T3 11 (25.6%) Pathological N Stage N0 39 (89.0%) N+ 4 (11.0%) Resection Status R0 20 (46.5%) R1 18 (41.9%) Rx 5 (11.6%) PSA at initial diagnosis (ng/mL) 30 (69.8%) <10 10-20 10 (23.2%) >20 3 (7.0%) Risk groups (D'Amico) Low 0 (0.0%) Intermediate 8 (18.6%) High 35 (81.4%) Risk groups (Stephensen) Low 25 (58.1%) Intermediate 7 (16.3%) High 7 (16.3%) High+ 4 (9.3%) Androgen Deprivation Therapy Pre-op 6 (13.9%) Pre-RT 3 (7.0%) Concurrent 4 (9.3%) Time from RP to RT (months) 34.5 Median (min-max) (10.4-123.1) Follow-up post-RT (years) 3.7 Median (min-max) (0.7-7.4) Pre-RT PSA (ng/mL) <0.2 6 (14.0%) 0.2-1.0 28 (65.1%) 1.0-5.0 7 (16.2%) >5.0 2 (4.7%) Time from RT to BF (months) 47.7 Median (min-max) (18.4-138.0) Recurrence following RT Biochemical 19 (44.2%) Proven by imaging 7 (16.3%) Inside RT field 0 (0.0%) Outside RT field 7 (16.3%)

Using these data, miRNA expression was correlated with time to first biochemical recurrence to determine if miRNAs can predict biochemical recurrence post-RP. Time to first recurrence was defined as the time from prostatectomy to the start date of salvage RT. Using tumor expression only, 54 miRNAs were identified that were significantly differentially expressed 1.5-fold or greater between patients who had an early (≦36 months) versus late (>36 months) recurrence (Table 6). Thirty six months was used as the cut-off as it was near the median of time to recurrence. For another approach to identify miRNAs that correlated with time to first biochemical recurrence, patients were dichotomized according to median miRNA expression. Probabilities in the time to the first recurrences were compared between the two groups (high versus low miRNA expression) using log-rank tests. One hundred and twenty three miRNAs were identified that could differentiate the two groups in the time to first biochemical recurrence (p-value<0.05) Table 7.

TABLE 6 miRNA comparisons between early vs. late recurrence via ANOVA analysis Ratio miR_ID (Late:Early) p-value Mean (Late) Mean (Early) hsa-miR-145-5p 0.32202 0.0007 1630.94 5064.73 hsa-miR-221-3p 0.42762 0.0001 58.83 137.58 hsa-miR-27b-3p 0.43656 0.0007 252.18 577.66 hsa-miR-200a-3p 0.45447 0.0026 109.13 240.12 hsa-miR-143-3p 0.4547 0.0031 2009.27 4418.93 hsa-miR-200b-3p 0.47031 0.0108 218.29 464.15 hsa-miR-26a-5p 0.49082 0.0108 710.78 1448.16 hsa-miR-29c-3p 0.49275 0.0017 363.69 738.07 hsa-miR-23b-3p 0.49425 0.0041 373.89 756.47 hsa-miR-24-3p 0.51956 0.0019 95.16 183.16 hsa-let-7e-5p 0.53013 0.0006 182.99 345.18 hsa-miR-130a-3p 0.53557 0.0028 185.47 346.3 hsa-miR-30c-5p 0.54826 0.0008 54.97 100.26 hsa-let-7f-5p 0.55346 0.0015 346.13 625.4 hsa-miR-195-5p 0.55717 0.002 101.2 181.64 hsa-miR-199a- 0.56099 0.0098 346.44 617.55 3p?miR-199b- hsa-miR-98 0.56358 0.0007 90.94 161.37 hsa-miR-720 0.56623 0.0049 9822.96 17347.9 hsa-miR-376a-3p 0.56675 0.0008 75.02 132.38 hsa-miR-361-5p 0.5668 0.0036 120.3 212.24 hsa-let-7a-5p 0.56943 0.0015 5104.76 8964.63 hsa-let-7c 0.5733 0.0017 759.01 1323.94 hsa-miR-23a-3p 0.57904 0.0087 649.3 1121.34 hsa-miR-1 0.58131 0.0148 63.43 109.11 hsa-miR-29b-3p 0.58301 0.009 1144.22 1962.61 hsa-miR-30b-5p 0.59435 0.0202 457.48 769.71 hsa-miR-125b-5p 0.60235 0.0076 4021.05 6675.64 hsa-let-7b-5p 0.60465 0.0015 2390.02 3952.71 hsa-miR-22-3p 0.60552 0.0034 259.6 428.72 hsa-miR-100-5p 0.60641 0.0067 429.42 708.13 hsa-miR-133a 0.61408 0.0294 12.54 52.98 hsa-miR-10b-5p 0.61835 0.008 45.37 73.37 hsa-miR-186-5p 0.61856 <.0001 49.96 80.78 hsa-miR-34a-5p 0.61913 0.0007 113.16 182.77 hsa-miR-99a-5p 0.62682 0.0164 8412.8 1342.14 hsa-miR-497-5p 0.62691 0.0137 81.88 130.61 hsa-miR-301b 0.628 0.0053 27.76 44.21 hsa-let-7g-5p 0.62865 0.012 1335.33 2124.12 hsa-miR-374b-5p 0.63133 0.0028 111.47 176.56 hsa-miR-125a-5p 0.63288 0.0025 101.97 161.11 hsa-miR-222-3p 0.63736 0.015 191.35 300.23 hsa-miR-199a-5p 0.63879 0.0082 130.97 205.04 hsa-miR-324-5p 0.64374 <.0001 57.02 88.57 hsa-miR-16-5p 0.64478 0.0266 377.17 584.96 hsa-miR-15a-5p 0.64586 0.0112 256.56 397.23 hsa-miR-429 0.6493 0.0489 60.01 92.42 hsa-let-7d-5p 0.65561 0.0014 166.14 253.42 hsa-miR-29a-3p 0.65694 0.0251 283.02 430.82 hsa-miR-342-3p 0.65812 0.028 192.38 292.32 hsa-miR-141-3p 0.65813 0.0285 545.9 829.48 hsa-miR-541-3p 1.51627 0.0057 26.71 17.29 hsa-miR-568 1.5289 0.0054 36.92 24.15 hsa-miR-342-5p 1.9266 0.0091 19.29 10.01 hsa-miR-137 2.69857 0.0111 233.38 86.48

TABLE 7 miRNAs that predict time to first recurrence via log-rank analysis p-value miR_ID (log-rank) hsa-miR-107 0.0001 hsa-miR-576-3p 0.0001 hsa-let-7f-5p 0.0003 hsa-miR-1286 0.0003 hsa-miR-486-3p 0.0003 hsa-miR-568 0.0005 hsa-miR-106b-5p 0.0006 hsa-miR-890 0.0006 hsa-miR-15a-5p 0.0007 hsa-miR-365a-3p 0.0007 hsa-miR-450b-5p 0.0007 hsa-miR-423-5p 0.0008 hsa-miR-572 0.0008 hsa-miR-29c-3p 0.0009 hsa-miR-28-5p 0.001 hsa-miR-302a-3p 0.0011 hsa-miR-548aa 0.0011 hsa-miR-324-5p 0.0014 hsa-miR-18b-5p 0.0015 hsa-miR-1260b 0.0016 hsa-miR-141-3p 0.0017 hsa-miR-922 0.0019 hsa-miR-148a-3p 0.0021 hsa-miR-148b-3p 0.0022 hsa-miR-98 0.0023 hsa-miR-193a-5p 0.0024 hsa-miR-191-5p 0.0025 hsa-miR-548ak 0.0027 hsa-miR-1908 0.0029 hsa-miR-548d-5p 0.0033 hsa-miR-375 0.0034 hsa-miR-660-5p 0.0034 hsa-miR-194-5p 0.0036 hsa-miR-483-3p 0.0037 hsa-miR-1257 0.0038 hsa-miR-4454 0.0038 hsa-let-7a-5p 0.0041 hsa-miR-638 0.0041 hsa-miR-30b-5p 0.0043 hsa-miR-30c-5p 0.0044 hsa-miR-106a-5p?miR-17-5p 0.0045 hsa-let-7e-5p 0.0046 hsa-miR-1276 0.0047 hsa-miR-516a-3p 0.0047 hsa-miR-30d-5p 0.0049 hsa-miR-320a 0.0049 hsa-miR-216a 0.0059 hsa-miR-1323 0.0063 hsa-miR-450b-3p 0.0069 hsa-miR-3136-5p 0.0074 hsa-let-7g-5p 0.0075 hsa-miR-93-5p 0.0075 hsa-miR-885-5p 0.0082 hsa-miR-1206 0.0085 hsa-miR-421 0.0085 hsa-miR-1200 0.0091 hsa-miR-548am-3p 0.0107 hsa-miR-34c-3p 0.0111 hsa-miR-3934 0.0112 hsa-miR-497-5p 0.0122 hsa-miR-1205 0.0123 hsa-miR-15b-5p 0.0123 hsa-miR-508-5p 0.0127 hsa-miR-409-3p 0.0128 hsa-miR-376a-3p 0.0134 hsa-miR-762 0.0138 hsa-miR-195-5p 0.0141 hsa-miR-654-5p 0.0151 hsa-miR-130a-3p 0.0153 hsa-miR-1290 0.0154 hsa-miR-1288 0.0157 hsa-miR-613 0.0163 hsa-miR-1279 0.0168 hsa-miR-376c 0.017 hsa-miR-135a-5p 0.0177 hsa-miR-23b-3p 0.0178 hsa-miR-1915-3p 0.0182 hsa-miR-27b-3p 0.0187 hsa-miR-362-5p 0.0195 hsa-miR-4448 0.0198 hsa-miR-196a-5p 0.0199 hsa-miR-541-3p 0.0203 hsa-miR-548l 0.0207 hsa-miR-570-3p 0.0214 hsa-miR-767-3p 0.0214 hsa-let-7d-5p 0.0215 hsa-miR-92a-3p 0.0219 hsa-miR-24-3p 0.0224 hsa-miR-221-3p 0.0225 hsa-miR-3168 0.0225 hsa-miR-199a-3p?miR-199b- 0.0237 hsa-miR-4508 0.0241 hsa-miR-374b-5p 0.0251 hsa-miR-548t-5p 0.0251 hsa-miR-3180 0.0252 hsa-miR-495 0.0279 hsa-miR-19b-3p 0.0286 hsa-miR-1180 0.0291 hsa-miR-3196 0.0304 hsa-miR-566 0.0325 hsa-miR-524-3p 0.0331 hsa-miR-429 0.0332 hsa-miR-145-5p 0.0361 hsa-let-7i-5p 0.0366 hsa-miR-29b-3p 0.0374 hsa-miR-137 0.0377 hsa-miR-149-5p 0.0378 hsa-miR-891b 0.0382 hsa-miR-514b-5p 0.0394 hsa-miR-549 0.0394 hsa-miR-513a-3p 0.0403 hsa-miR-548z 0.041 hsa-miR-511 0.0423 hsa-miR-99b-5p 0.0424 hsa-miR-548v 0.0438 hsa-miR-766-3p 0.0439 hsa-miR-1245b-5p 0.0445 hsa-miR-143-3p 0.0465 hsa-miR-877-5p 0.0465 hsa-miR-146b-5p 0.0473 hsa-miR-515-3p 0.0484 hsa-miR-1179 0.0485 hsa-miR-20a-5p?miR-20b-5p 0.0488

miRNAs Predictive of PSA Recurrence Post-Prostatectomy: Multivariate Analysis.

In order to determine if miRNAs can be independent markers of biochemical recurrence post-RP, two multivariate Cox regression analyses were performed using all 123 miRNAs identified to be predictive of biochemical recurrence post-prostatectomy (p-value<0.05) by univariate log-rank analysis Table 7. The first multivariate analysis considered initial PSA value (continuous) and Gleason score; age and resection status was eliminated as it did not seem to affect the recurrence in univariate analysis. Upon analysis of the first recurrence using multivariable Cox regression analysis, 97 miRNAs had p-values<0.05 (Table 8). In the second multivariate analysis, different clinical factors were taken into consideration. Three clinical covariates were examined independently, D'Amico score, Stephenson score (categorical), and Stephenson score (continuous), respectively to identify miRNAs associated with time to first recurrence. miRNAs were removed from further analysis if a significant p-value (<0.05) was not obtained in any of the three analyses which resulted in 88 miRNAs that were statistically associated with time to first recurrence after multivariate analysis (Table 2). Patients were classified into two groups using unbiased hierarchical cluster analysis for those selected 88 miRNAs (FIG. 3A). For FIGS. 3A-3B, cluster analysis was performed using the statistically significant 88 miRNAs predictive of first biochemical recurrence using Cox regression multivariable analysis (D'Amico score, Stephensen score (categorical), and Stephensen score (continuous). FIG. 3A demonstrates how this signature appears to differentiate between patients with early recurrence (<36 months) versus those with late recurrence (>36 months). FIG. 3B shows Kaplan-Meier plots that were generated using the two cluster groups. Cluster 1, the left cluster, is the early recurrence group. Cluster 2, the right cluster, is the late recurrence group. The Kaplan-Meier method showed that the probabilities in the time to first biochemical recurrence were significantly different between the two groups of patients with distinguished miRNA signatures (log-rank, p=0.005).

TABLE 8 miRNAs that predict time to first biochemical recurrence post-radical prostatectomy (RP) via multivariate Cox regression analysis Hazard Ratio miR_ID (High vs Low) p-value 95% CI hsa-miR-107 9.61 <.0001  (3.47, 26.58) hsa-miR-1915-3p 8.0464 0.0002  (2.65, 24.44) hsa-miR-106b-5p 5.5337 0.0008  (2.03, 15.09) hsa-miR-421 4.9287 <.0001  (2.28, 10.67) hsa-let-7f-5p 4.6887 0.0005  (1.98, 11.12) hsa-miR-18b-5p 4.6492 0.001  (1.87, 11.58) hsa-miR-106a-5p?miR-17-5p 4.565 0.0023  (1.72, 12.12) hsa-miR-15a-5p 4.4285 0.0016  (1.76, 11.13) hsa-miR-191-5p 4.1342 0.003  (1.62, 10.54) hsa-miR-1279 4.077 0.0015 (1.71, 9.73) hsa-miR-29c-3p 3.8189 0.0014 (1.68, 8.68) hsa-miR-4454 3.8179 0.0037 (1.55, 9.42) hsa-miR-93-5p 3.7934 0.0023 (1.61, 8.93) hsa-miR-376a-3p 3.7741 0.0013 (1.68, 8.47) hsa-miR-423-5p 3.7727 0.0014 (1.67, 8.54) hsa-miR-149-5p 3.5734 0.0008  (1.7, 7.52) hsa-miR-20a-5p?miR-20b-5p 3.4053 0.0074 (1.39, 8.35) hsa-miR-221-3p 3.3326 0.0025 (1.53, 7.27) hsa-miR-141-3p 3.1033 0.0113 (1.29, 7.45) hsa-miR-19b-3p 3.077 0.0201 (1.19, 7.94) hsa-miR-877-5p 3.0044 0.0149 (1.24, 7.28) hsa-miR-497-5p 3.0009 0.0052 (1.39, 6.49) hsa-miR-148a-3p 2.9478 0.0075 (1.33, 6.51) hsa-miR-27b-3p 2.9186 0.007 (1.34, 6.35) hsa-miR-30c-5p 2.916 0.0034 (1.42, 5.97) hsa-miR-28-5p 2.9121 0.0025 (1.46, 5.82) hsa-let-7e-5p 2.8575 0.0042 (1.39, 5.86) hsa-miR-376c 2.8526 0.0051 (1.37, 5.94) hsa-miR-324-5p 2.8459 0.0064 (1.34, 6.04) hsa-miR-98 2.8348 0.0031 (1.42, 5.66) hsa-miR-548aa 2.8047 0.0133 (1.24, 6.34) hsa-miR-30d-5p 2.7969 0.0085  (1.3, 6.01) hsa-miR-92a-3p 2.7473 0.016 (1.21, 6.25) hsa-miR-549 2.7108 0.0164  (1.2, 6.12) hsa-let-7g-5p 2.7026 0.0053 (1.34, 5.44) hsa-miR-570-3p 2.6726 0.0123 (1.24, 5.77) hsa-miR-365a-3p 2.5484 0.0241 (1.13, 5.75) hsa-miR-146b-5p 2.5192 0.0225 (1.14, 5.57) hsa-miR-23b-3p 2.4507 0.0129 (1.21, 4.97) hsa-miR-194-5p 2.4328 0.0246 (1.12, 5.28) hsa-let-7a-5p 2.4173 0.0116 (1.22, 4.8)  hsa-miR-483-3p 2.4078 0.0429 (1.03, 5.64) hsa-miR-130a-3p 2.3785 0.0139 (1.19, 4.74) hsa-miR-193a-5p 2.3649 0.0259 (1.11, 5.04) hsa-miR-3196 2.3296 0.0196 (1.15, 4.74) hsa-miR-195-5p 2.3243 0.0153 (1.18, 4.6)  hsa-miR-548v 2.3194 0.0484 (1.01, 5.35) hsa-miR-1260b 2.2893 0.0388 (1.04, 5.02) hsa-miR-374b-5p 2.2845 0.0228 (1.12, 4.65) hsa-miR-24-3p 2.2661 0.0204 (1.14, 4.52) hsa-miR-1290 2.2529 0.032 (1.07, 4.73) hsa-miR-199a-3p?miR-199b- 2.2506 0.0237 (1.11, 4.54) hsa-miR-135a-5p 2.2052 0.0232 (1.11, 4.36) hsa-let-7d-5p 2.121 0.0379 (1.04, 4.31) hsa-miR-3136-5p 0.4684 0.0344 (0.23, 0.95) hsa-miR-891b 0.4554 0.0418 (0.21, 0.97) hsa-miR-762 0.4527 0.0277 (0.22, 0.92) hsa-miR-1276 0.4493 0.0347 (0.21, 0.94) hsa-miR-1288 0.4302 0.015 (0.22, 0.85) hsa-miR-1205 0.4298 0.0173 (0.21, 0.86) hsa-miR-3180 0.4203 0.0266 (0.2, 0.9) hsa-miR-613 0.4178 0.0252 (0.19, 0.9)  hsa-miR-1257 0.4124 0.0323 (0.18, 0.93) hsa-miR-1323 0.4113 0.0329 (0.18, 0.93) hsa-miR-548l 0.408 0.0206 (0.19, 0.87) hsa-miR-922 0.4068 0.0257 (0.18, 0.9)  hsa-miR-508-5p 0.3865 0.0117 (0.18, 0.81) hsa-miR-516a-3p 0.3848 0.0219 (0.17, 0.87) hsa-miR-34c-3p 0.3818 0.0076 (0.19, 0.77) hsa-miR-3934 0.3657 0.0095 (0.17, 0.78) hsa-miR-548t-5p 0.3582 0.0067 (0.17, 0.75) hsa-miR-196a-5p 0.3462 0.0051 (0.16, 0.73) hsa-miR-890 0.3455 0.0123 (0.15, 0.79) hsa-miR-137 0.3454 0.0039 (0.17, 0.71) hsa-miR-486-3p 0.3411 0.0075 (0.16, 0.75) hsa-miR-511 0.3411 0.0168 (0.14, 0.82) hsa-miR-885-5p 0.3404 0.0034 (0.17, 0.7)  hsa-miR-495 0.3343 0.0028 (0.16, 0.69) hsa-miR-638 0.3327 0.0029 (0.16, 0.69) hsa-miR-766-3p 0.3316 0.0029 (0.16, 0.69) hsa-miR-320a 0.3305 0.0085 (0.14, 0.75) hsa-miR-1200 0.3237 0.0039 (0.15, 0.7)  hsa-miR-566 0.3135 0.0084 (0.13, 0.74) hsa-miR-450b-5p 0.3114 0.0064 (0.13, 0.72) hsa-miR-4508 0.3077 0.0024 (0.14, 0.66) hsa-miR-548ak 0.2636 0.0011 (0.12, 0.59) hsa-miR-1908 0.2623 0.0027 (0.11, 0.63) hsa-miR-409-3p 0.2597 0.0017 (0.11, 0.6)  hsa-miR-1286 0.2488 0.0016  (0.1, 0.59) hsa-miR-450b-3p 0.2468 0.0027  (0.1, 0.61) hsa-miR-654-5p 0.2446 0.0003 (0.11, 0.53) hsa-miR-576-3p 0.209 0.0004 (0.09, 0.5)  hsa-miR-216a 0.1914 0.0001 (0.08, 0.45) hsa-miR-568 0.18 0.0007 (0.07, 0.49) hsa-miR-302a-3p 0.1646 0.0002 (0.06, 0.42) hsa-miR-572 0.1507 <.0001 (0.06, 0.35) hsa-miR-1180 0.1279 0.0002 (0.04, 0.38)

miRNAs Predictive of PSA Recurrence Post-Salvage RT: Univariate Analysis.

miRNAs that could predict biochemical recurrence after salvage RT treatment are of utmost interest. At this time, no studies have examined miRNAs associated with clinical outcomes following post-RP salvage radiation. The recurrence after salvage radiation treatment (also referred to as the 2^(nd) recurrence) was defined as a rise in PSA to ≧0.2 ng/mL at least twice consecutively following the nadir (Cookson et al., Journal of Urology, 2007). In the patient cohort, 19/43 patients experienced biochemical recurrence after salvage radiotherapy Table 5. Further, using tumor miRNA expression only, 4 miRNAs were identified that were significantly expressed 1.5-fold or greater in patients who experienced a second recurrence when compared with those who did not (p-value<0.05) (Table 9). In the univariate log-rank analysis, 24 miRNAs were identified, which could predict those who recurred a second time after salvage RT from those who did not recur (p-value<0.05) (Table 10).

TABLE 9 miRNAs that predict biochemical recurrence post-salvage radiation therapy (RT) via ANOVA Ratio (Recurrence:Non- p- Mean Mean miR_ID recurrence) value (Non-recurrence) (Recurrence) hsa-miR- 0.63 0.008 213.5 133.89 4443 hsa-miR- 0.65 0.002 38.89 25.45 626 hsa-miR- 0.67 <.0001 33.95 22.64 1202 hsa-miR- 1.61 0.009 47.5 76.6 10b-5p

TABLE 10 miRNAs that predict biochemical recurrence post-salvage radiation therapy (RT) via log-rank analysis miR_ID p-value (log-rank) hsa-miR-628-3p 0.0028 hsa-miR-924 0.0039 hsa-miR-626 0.0056 hsa-miR-1202 0.0096 hsa-miR-563 0.0234 hsa-miR-598 0.0249 hsa-miR-30d-5p 0.0293 hsa-miR-491-5p 0.0298 hsa-miR-4516 0.0326 hsa-miR-601 0.0327 hsa-miR-508-3p 0.0356 hsa-miR-576-5p 0.0358 hsa-miR-320e 0.0394 hsa-miR-134 0.0401 hsa-miR-548an 0.043 hsa-miR-1303 0.0443 hsa-miR-551a 0.0449 hsa-miR-761 0.0464 hsa-miR-1244 0.0469 hsa-miR-96-5p 0.0471 hsa-miR-658 0.0476 hsa-miR-1193 0.0481 hsa-miR-597 0.0482 hsa-miR-1913 0.0483

miRNAs Predictive of PSA Recurrence Post-Salvage RT:

Multivariate Analysis. Similarly, in order to determine if miRNAs can independently predict biochemical recurrence post-salvage RT, multivariate Cox regression analyses were performed using the 24 miRNAs that were significantly associated (p-value<0.05) with recurrence post-salvage RT by univariate log-rank analysis (Table 10). Due to the small sample size and number of events, only two covariates were examined in the multivariate analysis. The multivariate analysis was performed using lymph node status and Gleason score (these factors were chosen as having the lowest p-values upon univariate analysis as shown in (Table 11), leading to identification of 9 miRNAs that predict biochemical recurrence post-salvage RT (Table 3).

TABLE 11 Univariate analysis for molecular and clinical variables Time to Failure Failure Post-RP Post-Salvage RT p-value p-value 88 miRNA cluster 0.005 n/a Predictive Salvage RT Model n/a <0.001 Gleason Score 0.36 0.02 Lymph Node Involvement 0.11 0.001 Positive Resection Status 0.99 0.13 Pathologic Tumor Stage 0.1 0.38 PSA 0.63 (pre-op) 0.29 (pre-RT) D'Amico 0.01 0.88 Stephenson (post-RP) 0.002 0.04

Predictive Effect of miR-601+miR-4516 & Development of a miRNA-Based Predictive Salvage RT Model.

Lymph node status, Gleason score and the 9 miRNAs were used as covariates in a COX regression model and stepwise model selection strategy was used to capture miRNAs which could be good candidates in predicting the biochemical recurrence post-salvage RT. The two miRNAs, miR-601 and miR-4516 alone and together with Gleason score and lymph node status were selected by the model. FIG. 4 shows an area under the receiver operating characteristic curve (AUC) of a miRNA-based predictive salvage RT model. The curve was generated using the nearest neighbor estimation method (Heagerty et al. Biometrics, 2000). Specifically, AUC curves were generated using a stepwise Cox regression model to determine a signature predictive of biochemical recurrence post-salvage radiation therapy. An AUC for lymph node and Gleason score was found to be 0.66, the addition of miR-601 and miR-4516 increased the AUC to 0.83 (FIG. 4). Interestingly, each miRNA alone (miR-601 AUC=0.77 and miR-4516 AUC=0.68) or together (miR-601+miR-4516 AUC=0.76) (FIG. 4) had a better predictive capability than the combination of positive lymph nodes together with Gleason score (FIG. 4).

FIG. 5 is a Kaplan-Meier plot that shows estimates of miRNA-based predictive salvage RT model. The plot was generated using the miR-4516+miR-601+Gleason score+lymph node status model for biochemical recurrence post salvage radiation therapy. Using the median risk score generated by this model (miR-4516, miR-601, Gleason score, and lymph node status), patients were classified as high or low risk groups. The probabilities in recurrence post-salvage RT of the two groups were found to be significantly different (log-rank, p<0.01).

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. 

1. A method for predicting biochemical recurrence in a subject following radical prostatectomy, comprising a) determining a miRNA expression profile from a sample from the subject of at least 1 miRNA listed in Table 2; and b) calculating a recurrence risk score from the miRNA expression profile; wherein a high recurrence risk score is an indication of biochemical recurrence within 1 to 5 years.
 2. A method for predicting biochemical recurrence in a subject following post-prostatectomy salvage radiation therapy, comprising a) determining a miRNA expression profile from a sample from the subject of at least 1 miRNA listed in Table 3; and b) calculating a recurrence risk score from the miRNA expression profile; wherein a high recurrence risk score is an indication of biochemical recurrence within 1 to 5 years.
 3. The method of claim 1, further comprising grading a tumor according to a Gleason score, and using the Gleason score as a covariate in calculating the recurrence risk score.
 4. The method of claim 1, further comprising determining one or more properties of a tumor including the subject's age, PSA levels, lymph node classification (pN), pathologic tumor classification (pT), resection status, D'Amico classification, and/or Stephenson nomograms and using the one or more properties as covariates in calculating the recurrence risk score.
 5. The method of claim 2, wherein the at least 1 miRNA comprises miR-4516, miR-601, or a combination thereof.
 6. The method of claim 1, further comprising selecting a treatment based on the recurrence risk score.
 7. The method of claim 6, comprising treating the subject radical prostatectomy, or radiation therapy, if the recurrence risk score is high.
 8. The method of claim 6, comprising treating the subject palliative care is selected if the recurrence risk score is high.
 9. The method of claim 6, comprising treating the subject with an adjuvant therapy if the recurrence risk score is high.
 10. The method of claim 9, wherein the adjuvant therapy comprises chemotherapy, hormone therapy, biologic therapy, radiation therapy, or a combination thereof.
 11. The method of claim 6, comprising treating the subject with salvage radiation therapy if the recurrence risk score is high.
 12. The method of claim 11, wherein the salvage radiation therapy comprises external beam radiation therapy or internal radiation therapy.
 13. The method of claim 6, comprising continued clinical monitoring if the recurrence risk score is low.
 14. A method of screening for prostate cancer in a subject, comprising assaying a sample from the subject for levels of miRNA-1283, miRNA-137, or a combination thereof, and comparing the levels to control values, wherein a decrease in miRNA-1283 levels, miRNA-137 levels, or a combination thereof, is an indication that the subject has a prostate cancer.
 15. The method of claim 14, further comprising determining a PSA level for the subject.
 16. The method of claim 14, further comprising taking a prostate biopsy.
 17. The method of claim 14, further comprising treating the subject with surgical treatment, radiation treatment, adjuvant treatment, or any combination thereof if prostate cancer is indicated.
 18. The method of claim 14, further comprising continued clinical monitoring if prostate cancer is not indicated.
 19. The method of claim 1, wherein the sample is a tumor or a bodily fluid.
 20. (canceled) 